<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ANP</journal-id>
<journal-id journal-id-type="hwp">spanp</journal-id>
<journal-title>Australian &amp; New Zealand Journal of Psychiatry</journal-title>
<issn pub-type="ppub">0004-8674</issn>
<issn pub-type="epub">1440-1614</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0004867411432074</article-id>
<article-id pub-id-type="publisher-id">10.1177_0004867411432074</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>The role of alprazolam for the treatment of panic disorder in Australia</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Moylan</surname><given-names>Steven</given-names></name>
<xref ref-type="aff" rid="aff1-0004867411432074">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Giorlando</surname><given-names>Francesco</given-names></name>
<xref ref-type="aff" rid="aff2-0004867411432074">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Nordfjærn</surname><given-names>Trond</given-names></name>
<xref ref-type="aff" rid="aff3-0004867411432074">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Berk</surname><given-names>Michael</given-names></name>
<xref ref-type="aff" rid="aff1-0004867411432074">1</xref>
<xref ref-type="aff" rid="aff2-0004867411432074">2</xref>
<xref ref-type="aff" rid="aff4-0004867411432074">4</xref>
<xref ref-type="aff" rid="aff5-0004867411432074">5</xref>
</contrib>
</contrib-group>
<aff id="aff1-0004867411432074"><label>1</label>School of Medicine, Deakin University, Geelong, Australia</aff>
<aff id="aff2-0004867411432074"><label>2</label>Department of Psychiatry, University of Melbourne, Parkville, Australia</aff>
<aff id="aff3-0004867411432074"><label>3</label>Drug and Alcohol Treatment in Central Norway, Department for Research and Development, Norway</aff>
<aff id="aff4-0004867411432074"><label>4</label>Orygen Youth Health Research Centre, Parkville, Australia</aff>
<aff id="aff5-0004867411432074"><label>5</label>Mental Health Research Institute, Parkville, Australia</aff>
<author-notes>
<corresp id="corresp1-0004867411432074">Steven Moylan, School of Medicine, Deakin University, c/o Swanston Centre, Barwon Health, Geelong, VIC 3220, Australia. Email: <email>steven.moylan@deakin.edu.au</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2012</year>
</pub-date>
<volume>46</volume>
<issue>3</issue>
<fpage>212</fpage>
<lpage>224</lpage>
<permissions>
<copyright-statement>© The Royal Australian and New Zealand College of Psychiatrists 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">The Royal Australian and New Zealand College of Psychiatrists</copyright-holder>
</permissions>
<abstract>
<p><bold>Objective</bold>: To investigate the potential impact of increasing prescription rates of alprazolam for the treatment of panic disorder (PD) in Australia through a review of efficacy, tolerability and adverse outcome literature.</p>
<p><bold>Methods</bold>: Data were sourced by a literature search using MEDLINE, Embase, PsycINFO and a manual search of scientific journals to identify relevant articles. Clinical practice guidelines from the American Psychiatric Association, National Institute of Clinical Excellence, Royal Australian and New Zealand College of Psychiatrists and World Federation of Societies of Biological Psychiatry were sourced. Prescription data were sourced from Australian governmental sources.</p>
<p><bold>Results</bold>: Alprazolam has shown efficacy for control of PD symptoms, particularly in short-term controlled clinical trials, but is no longer recommended as a first-line pharmacological treatment due to concerns about the risks of developing tolerance, dependence and abuse potential. Almost no evidence is available comparing alprazolam to current first-line pharmacological treatment. Despite this, prescription rates are increasing. A number of potential issues including use in overdose and impact on car accidents are noted.</p>
<p><bold>Conclusion:</bold> Although effective for PD symptoms in clinical trials, a number of potential issues may exist with use. Consideration of its future place in PD treatment in Australia may be warranted.</p>
</abstract>
<kwd-group>
<kwd>Panic disorder</kwd>
<kwd>alprazolam</kwd>
<kwd>efficacy</kwd>
<kwd>prescription</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0004867411432074" sec-type="intro">
<title>Introduction</title>
<p>Alprazolam is a high potency triazolobenzodiazepine subsidised for use through the Australian Government Pharmaceutical Benefits Scheme (PBS) in Australia for panic disorder (PD) ‘where other treatments have failed or are inappropriate’ (<xref ref-type="bibr" rid="bibr15-0004867411432074">Australian Government Department of Health and Ageing, 2011</xref>). Before the selective serotonin reuptake inhibitors (SSRIs) became available (<xref ref-type="bibr" rid="bibr16-0004867411432074">Bakker et al., 2000</xref>; <xref ref-type="bibr" rid="bibr133-0004867411432074">Westernberg, 1996</xref>), alprazolam was a recommended first-line agent in the treatment of PD (<xref ref-type="bibr" rid="bibr19-0004867411432074">Balestrieri et al., 1989</xref>; <xref ref-type="bibr" rid="bibr20-0004867411432074">Ballenger, 1986</xref>; <xref ref-type="bibr" rid="bibr68-0004867411432074">Lesser, 1991</xref>; <xref ref-type="bibr" rid="bibr119-0004867411432074">Sheehan, 1987</xref>; <xref ref-type="bibr" rid="bibr131-0004867411432074">Vittone and Uhde, 1985</xref>). However, concerns regarding potential long-term issues with its use (<xref ref-type="bibr" rid="bibr1-0004867411432074">Abelson and Curtis, 1993</xref>; <xref ref-type="bibr" rid="bibr53-0004867411432074">Fyer et al., 1987</xref>; <xref ref-type="bibr" rid="bibr86-0004867411432074">Noyes et al., 1991</xref>; <xref ref-type="bibr" rid="bibr91-0004867411432074">Pecknold, 1993</xref>; <xref ref-type="bibr" rid="bibr92-0004867411432074">Pecknold et al., 1988</xref>) and availability of better tolerated alternatives led to its removal (<xref ref-type="bibr" rid="bibr82-0004867411432074">National Institute for Health and Clinical Excellence, 2011</xref>) or relegation to second- or third-line status (<xref ref-type="bibr" rid="bibr2-0004867411432074">American Psychiatric Association, 2009</xref>; <xref ref-type="bibr" rid="bibr26-0004867411432074">Bandelow et al., 2008</xref>; <xref ref-type="bibr" rid="bibr107-0004867411432074">Royal Australian and New Zealand College of Psychiatrists, 2003</xref>) in PD treatment guidelines. Despite this relegation, prescription of alprazolam continues to grow. In the decade between 1997 and 2007, PBS-subsidised prescription of alprazolam grew by 93% to 386,350 prescriptions (<xref ref-type="bibr" rid="bibr14-0004867411432074">Australian Government Department of Health and Ageing, 2010</xref>). Over the same period, overall prescription of alprazolam (including by private prescription) grew by 99% (<xref ref-type="bibr" rid="bibr13-0004867411432074">Australian Government Department of Health and Ageing, 2008</xref>). Similar increases in prescription rates have been seen in the USA, with a 71% rise over the same period (<xref ref-type="bibr" rid="bibr115-0004867411432074">SDI/Verispan, 2008a</xref>). In that country, alprazolam is amongst the top 10 most prescribed medications, and is the most prescribed psychotropic (<xref ref-type="bibr" rid="bibr114-0004867411432074">SDI/Verispan, 2008a</xref>,<xref ref-type="bibr" rid="bibr115-0004867411432074">b</xref>, <xref ref-type="bibr" rid="bibr116-0004867411432074">2010</xref>; <xref ref-type="bibr" rid="bibr28-0004867411432074">Belouin, 2008</xref>).</p>
<p>This review aims to discuss key issues related to alprazolam use for PD in Australia, with a focus on the discordance between increasing prescription rates, the evidence regarding its risk–benefit ratio and clinical practice guidelines. In particular, the review aims to discuss:</p>
<list id="list1-0004867411432074" list-type="bullet">
<list-item><p>The guideline-recommended role for alprazolam in PD</p></list-item>
<list-item><p>The current prescription of alprazolam in Australia</p></list-item>
<list-item><p>The relative effectiveness of alprazolam in PD compared to alternative pharmacological agents</p></list-item>
<list-item><p>The tolerability issues associated with alprazolam in the short and long term</p></list-item>
<list-item><p>Potential wider issues associated with alprazolam use</p></list-item>
<list-item><p>The potential role of alprazolam in the future treatment of PD</p></list-item>
</list>
<p>Data were sourced by a literature search using MEDLINE, Embase, PsycINFO and a manual search of scientific journals to identify relevant articles using the terms ‘panic’ and ‘alprazolam’. Clinical practice guidelines from the American Psychiatric Association (APA), National Institute of Clinical Excellence (NICE), Royal Australian and New Zealand College of Psychiatrists (RANZCP) and World Federation of Societies of Biological Psychiatry (WFSBP) were sourced. Prescription data were sourced from Australian governmental sources.</p>
</sec>
<sec id="section2-0004867411432074">
<title>The role of alprazolam in PD treatment according to guidelines</title>
<p>Numerous clinical practice guidelines (<xref ref-type="bibr" rid="bibr2-0004867411432074">American Psychiatric Association, 2009</xref>; <xref ref-type="bibr" rid="bibr26-0004867411432074">Bandelow et al., 2008</xref>; <xref ref-type="bibr" rid="bibr82-0004867411432074">National Institute for Health and Clinical Excellence, 2011</xref>; <xref ref-type="bibr" rid="bibr107-0004867411432074">Royal Australian and New Zealand College of Psychiatrists, 2003</xref>) are available for management of PD. All guidelines provide recommendations on the use of specific medication classes (e.g. benzodiazepines, SSRIs) and not individual compounds in PD treatment. In this context, the role of alprazolam in PD is covered by the role of benzodiazepines generally.</p>
<p>All major treatment guidelines recommend the SSRIs as first-line pharmacological agents, but equally stress the role of appropriate psychological therapies (<xref ref-type="bibr" rid="bibr2-0004867411432074">American Psychiatric Association, 2009</xref>; <xref ref-type="bibr" rid="bibr26-0004867411432074">Bandelow et al., 2008</xref>; <xref ref-type="bibr" rid="bibr82-0004867411432074">National Institute for Health and Clinical Excellence, 2011</xref>; <xref ref-type="bibr" rid="bibr107-0004867411432074">Royal Australian and New Zealand College of Psychiatrists, 2003</xref>). A contributing factor to this recommendation is the high rate of comorbid depressive and substance use disorders in patients suffering from PD (<xref ref-type="bibr" rid="bibr66-0004867411432074">Kessler et al., 2006</xref>). Data from the National Comorbidity Survey Replication in the USA demonstrated that approximately 35% of patients with PD or PD with agoraphobia suffer from comorbid major depressive disorder, and between 27% and 37% of patients suffer from comorbid substance use disorder (<xref ref-type="bibr" rid="bibr66-0004867411432074">Kessler et al., 2006</xref>). The SSRIs (and alternate antidepressant medications) have advantages in treating comorbid depressive disorders and as a consequence of their lack of abuse liability are preferred over the benzodiazepines for patients with current or past history of substance use disorders (<xref ref-type="bibr" rid="bibr2-0004867411432074">American Psychiatric Association, 2009</xref>).</p>
<p>The reported role of benzodiazepines is inconsistent across guidelines, but all guidelines suggest use beyond the short term may be inappropriate.</p>
<p>The NICE guidelines state: ‘benzodiazepines are associated with a less good outcome in the long term and should not be prescribed for the treatment of individuals with panic disorder’ (<xref ref-type="bibr" rid="bibr82-0004867411432074">National Institute for Health and Clinical Excellence, 2011</xref>). The APA guidelines cite evidence supporting earlier symptom response in patients co- administered a benzodiazepine with antidepressants. In this context they recommend ‘benzodiazepines may be used along with antidepressants to help control symptoms until the antidepressant takes effect, followed by slow tapering of the benzodiazepine’ (<xref ref-type="bibr" rid="bibr2-0004867411432074">American Psychiatric Association, 2009</xref>). However, they continue to state that the short-term benefit of benzodiazepines must be balanced against ‘the possibility that the patient may have difficulty tolerating the tapering and discontinuation of benzodiazepine; with ongoing use, all benzodiazepines will produce physiological dependence in most patients’ (<xref ref-type="bibr" rid="bibr2-0004867411432074">American Psychiatric Association, 2009</xref>). The WFSBP guidelines support benzodiazepines (alprazolam, clonazepam, diazepam and lorazepam) as exhibiting the same category of evidence (‘A’) as first-line pharmacological treatments for PD (SSRIs, venlafaxine). However, the guidelines provide similar advice to the APA guidelines, in that beyond short-term co-administration with the antidepressants the use of benzodiazepines should be restricted to treatment-resistant cases. There is an additional caveat restricting use to ‘when the patient does not have a history of dependency’ (<xref ref-type="bibr" rid="bibr26-0004867411432074">Bandelow et al., 2008</xref>). The RANZCP clinical practice guidelines for PD have not been updated since 2003, but state clearly that although evidence supports the effectiveness of SSRIs, tricyclic antidepressants (TCAs) and high-potency benzodiazepines, ‘benzodiazepine use is not recommended because of the high risk of creating dependency on these drugs’ (<xref ref-type="bibr" rid="bibr107-0004867411432074">Royal Australian and New Zealand College of Psychiatrists, 2003</xref>).</p>
</sec>
<sec id="section3-0004867411432074">
<title>The current use of alprazolam in Australia</title>
<p>Alprazolam prescription (both PBS-subsidised and private) has grown steadily over the last decade. This appears to coincide with an increase in overall drug utilisation. The defined daily dose (DDD) corresponds to the assumed average daily maintenance dose utilised for a drug’s main indication (<xref ref-type="bibr" rid="bibr136-0004867411432074">World Health Organization, 2011a</xref>) and is defined as 1 mg for alprazolam.A recent investigation by <xref ref-type="bibr" rid="bibr59-0004867411432074">Hollingworth and Siskind (2010)</xref> found that on a population level, total drug utilisation of alprazolam in Australia increased from 3.88 (DDD/1000 population/day)in 2003 to 5.12 (DDD/1000 population/day) in 2007.There are many potential non-mutually exclusive reasons why prescription and utilisation of alprazolam is increasing, including:</p>
<list id="list2-0004867411432074" list-type="bullet">
<list-item><p>Increased prescription due to increasing rates of PD.</p></list-item>
<list-item><p>Increased prescription due to ineffectiveness of guideline-recommended treatments.</p></list-item>
<list-item><p>Increased prescription due to clinician preference, against guideline recommendations.</p></list-item>
<list-item><p>Increased prescription due to patient preference or demand.</p></list-item>
<list-item><p>Prescription as a co-administered medication (e.g. as needed ‘PRN’).</p></list-item>
<list-item><p>Prescription for conditions other than PD (against PBS rules).</p></list-item>
</list>
<sec id="section4-0004867411432074">
<title>Increased prescription due to increasing rates of PD</title>
<p>Increasing utilisation of alprazolam may be secondary to an increase in the prevalence of PD. Population-based mental health surveys demonstrate that the rate of PD in Australia has increased from a 12-month prevalence of 1.3% (170,500 people) in 1997 (<xref ref-type="bibr" rid="bibr8-0004867411432074">Australian Bureau of Statistics, 1997</xref>) to an estimated 2.6% (410,000 people) in 2007 (<xref ref-type="bibr" rid="bibr9-0004867411432074">Australian Bureau of Statistics, 2007a</xref>). In the same period, overall prescriptions of alprazolam have increased from an estimated 308,810 in 1997 (<xref ref-type="bibr" rid="bibr12-0004867411432074">Australian Government Department of Health and Ageing, 1997</xref>) to 616,447 in 2007 (<xref ref-type="bibr" rid="bibr13-0004867411432074">Australian Government Department of Health and Ageing, 2008</xref>). Matching these statistics, the rate of alprazolam prescription appears to have decreased from 1.81 per patient/per year in 1997 to approximately 1.50 per patient/per year over this period. This decrease suggests increasing rates of PD may account in part for the increased number of alprazolam prescriptions. Care must, however, be taken when interpreting changes observed in these population-based surveys. The 2007 survey utilised two additional questions to determine presence of panic attacks, utilised different questions to establish the recurrent and unexpected nature of panic attacks, and did not exclude a diagnosis of PD if due to a co-occurring affective disorder (<xref ref-type="bibr" rid="bibr10-0004867411432074">Australian Bureau of Statistics, 2007b</xref>). As a consequence, the increase in PD may be at least partially explained by methodological changes, either through providing an overestimate of the true 12-month PD prevalence in 2007 or by correcting an underestimate recorded in 1997.</p>
<p>Even if the change in PD prevalence is a true finding, the co-occurring increase in alprazolam prescription is surprising considering the change in clinical practice recommendations over this period. The APA’s first guideline for PD was published in 1998 (<xref ref-type="bibr" rid="bibr3-0004867411432074">American Psychiatric Association, 1998</xref>) before which alprazolam was a recommended first-line treatment. The release of the APA, NICE, RANZCP and WFSBP guidelines in the ensuing decade recommended antidepressants as first-line pharmacological treatment for PD and would be expected to have decreased the utilisation of alprazolam.</p>
</sec>
<sec id="section5-0004867411432074">
<title>Increased prescription due to ineffectiveness of recommended treatments</title>
<p>Government-subsidised supply of alprazolam through the PBS is only available for the treatment of diagnosed PD where ‘other treatments have failed or are inappropriate’ (<xref ref-type="bibr" rid="bibr15-0004867411432074">Australian Government Department of Health and Ageing, 2011</xref>). It is difficult to quantify how many patients with PD may fit into this category. The psychological therapies and antidepressants are generally well-tolerated interventions (although they do carry their own specific side effects), and in few patients would their use be considered inappropriate. Rates of treatment response in PD utilising antidepressants vary between studies (60–80%) (<xref ref-type="bibr" rid="bibr93-0004867411432074">Perna et al., 2001</xref>; <xref ref-type="bibr" rid="bibr95-0004867411432074">Pollack et al., 2007</xref>), although a significant proportion of patients (20–40%) have been shown to have continued symptoms after an initial trial of treatment (<xref ref-type="bibr" rid="bibr23-0004867411432074">Bandelow et al., 2004</xref>; <xref ref-type="bibr" rid="bibr31-0004867411432074">Black et al., 1993</xref>). In cases of initial treatment non-response, treatment algorithms suggest dose augmentation, psychological and physical treatments (e.g. exercise). If treatment resistance continues, switching to another first-line pharmacological agent, e.g. SSRI, serotonin and noradrenaline reuptake inhibitor (SNRI), prior to TCAs (second-line agents) is recommended. It is only after multiple failed trials that benzodiazepines (third-line agents) are recommended (<xref ref-type="bibr" rid="bibr22-0004867411432074">Bandelow and Ruther, 2004</xref>). If treatment algorithms and guidelines are followed and trials of appropriate psychological therapies and antidepressant medications are undertaken, it would be expected that the number of patients with persisting treatment resistance would be low, although limited evidence exists in this area.</p>
</sec>
<sec id="section6-0004867411432074">
<title>Increased prescription due to clinician preference, against guideline recommendations</title>
<p>Some evidence exists that use of benzodiazepines in PD may persist in preference to guideline-recommended treatments. In the Harvard Brown Anxiety Research Project, a group of 443 patients with PD had their use of psychotropic medications monitored over 10 years. In the final year of follow-up (2001) more patients were receiving benzodiazepines as a sole treatment agent (36.2%) than benzodiazepines in combination with antidepressants (21.7%) or SSRIs alone (11.2%). This use was in clear contrast to clinical guideline recommendations (<xref ref-type="bibr" rid="bibr34-0004867411432074">Bruce et al., 2003</xref>).</p>
<p>Numerous studies across medical disciplines demonstrate that despite their advantages, clinical practice guidelines are not adhered to (<xref ref-type="bibr" rid="bibr56-0004867411432074">Hayward, 1997</xref>; <xref ref-type="bibr" rid="bibr70-0004867411432074">Lomas et al., 1989</xref>). <xref ref-type="bibr" rid="bibr36-0004867411432074">Cabana et al. (1999)</xref> suggest multiple barriers that can affect physician adherence to clinical guidelines, including scepticism, lack of awareness or familiarity with guidelines, a lack of outcome expectancy or self-efficacy to follow the practice guidelines and the inertia of previous practice patterns (being unable or unmotivated to change practice). In addition, barriers related to the guidelines themselves (usability, generalisability and convenience) and to patients (patient preference for a particular treatment course) were nominated as contributing factors.</p>
<p>Continued use of alprazolam may be influenced by prescribers’ past experiences, short-term outcome expectancy and by patient preference. Alprazolam often exhibits a much faster onset of action than the antidepressants in reducing anxiety, and learning theory suggests that the shorter the duration between the treatment and the response, the more likely behaviour will be reinforced. Clinicians’ desire to relieve distress as rapidly as possible may also drive preference for use over guideline-recommended treatments. In addition, alprazolam has demonstrated preferential tolerability and decreased treatment discontinuation in comparison to the TCAs in treatment trials (<xref ref-type="bibr" rid="bibr113-0004867411432074">Schweizer et al., 1993</xref>) and in clinical audits (<xref ref-type="bibr" rid="bibr44-0004867411432074">Cowley et al., 1997</xref>), a factor that may drive prescriber preference. The drop-out rates of SSRIs, however, appear lower than TCAs due to side effects (<xref ref-type="bibr" rid="bibr17-0004867411432074">Bakker et al., 2002</xref>). Unfortunately direct comparative data between SSRIs and alprazolam are very limited.</p>
</sec>
<sec id="section7-0004867411432074">
<title>Increased prescription due to patient preference or demand</title>
<p>Patients may prefer the use of alprazolam to the antidepressants due to the rapid rate of onset and increased tolerability. However, there is some evidence that alprazolam use is increasing faster than other benzodiazepines that exhibit similar advantages. While alprazolam use in Australia is estimated to have increased from 3.88 DDD/1000 pop/day to 5.12 DDD/1000 pop/day between 2003 and 2007, the use of other benzodiazepines including diazepam (6.16 DDD/1000 pop/day to 6.20 DDD/1000 pop/day), oxazepam (3.01 DDD/1000 pop/day to 2.48 DDD/1000 pop/day), lorazepam (0.36 DDD/1000 pop/day to 0.42 DDD/1000 pop/day) and temazepam (5.35 DDD/1000 pop/day to 4.65 DDD/1000 pop/day) demonstrated only minor increases or decreases in utilisation (<xref ref-type="bibr" rid="bibr59-0004867411432074">Hollingworth and Siskind, 2010</xref>).</p>
<p>It is unclear why alprazolam use is trending differently to other benzodiazepines. One factor may be patient preference related to dependence. Alprazolam, and benzodiazepines in general, have drawn vacillating opinion over the years as to their propensity to cause dependence and/or addiction (<xref ref-type="bibr" rid="bibr103-0004867411432074">Rosenbaum, 1993</xref>).</p>
<p>Addiction can be defined in a number of different ways.Some definitions imply that pleasure seeking with increasing dose is required for the syndrome.However, the more preferable definition is that of the World Health Organization (WHO) in which the addicted individual experiences a ‘compulsion to take the preferred substance, has great difficulty ceasing or modifying substance use and exhibits determination to obtain (the substance) by almost any means’ (<xref ref-type="bibr" rid="bibr137-0004867411432074">World Health Organization, 2011b</xref>).</p>
<p>The definition of addiction does not absolutely require tolerance or physical dependence but always involves behaviours that accompany psychological dependence.These behaviours, however, may be subtle when the substance is readily available or prescribed.In this context patients who struggle to withdraw or dose reduce due to the severe anxiety associated with withdrawal from alprazolam can be considered addicted.The main contention to this argument is that the patient’s failure to withdraw represents the underlying efficacy of the treatment (relapse). The difficulty in disentangling the source of anxiety (underlying or drug-induced) is a factor that complicates prescription and can be considered an undesirable quality of the pharmacotherapy.It is probable that both mechanisms may be operating simultaneously. This clinical conundrum is similar to the case of the patient who has pain but is opiate dependent.</p>
<p>A number of issues must be considered in attempting to quantify the impact of dependence and potential for harm, described in the following sections.</p>
</sec>
<sec id="section8-0004867411432074">
<title>Pharmacological properties related to addiction</title>
<p>A combination of pharmacokinetic and pharmacodynamic properties result in a drug’s addictive profile, and evidence is emerging that alprazolam may have more potent effects than other benzodiazepines upon reward pathways.Benzodiazepines, like all known addictive substances, alter mesolimbic dopaminergic pathways. Changes to evoked post-synaptic currents in the ventral tegmental area in mice can be detected after even a single dose of benzodiazepine (<xref ref-type="bibr" rid="bibr124-0004867411432074">Tan et al., 2010</xref>). It is hypothesised that this effect is mediated by GABA-A inhibition causing secondary disinhibition of dopaminergic neurons.</p>
<p>While alprazolam has been associated with more severe withdrawal than other benzodiazepines, it has been more difficult to assess whether it is truly more addictive (<xref ref-type="bibr" rid="bibr108-0004867411432074">Rush et al., 1993</xref>). There is some evidence that it produces more subjective euphoria, for example a study in patients addicted to opiates and receiving methadone revealed that they preferred alprazolam to other benzodiazepines (<xref ref-type="bibr" rid="bibr61-0004867411432074">Iguchi et al., 1989</xref>).</p>
<p>Alprazolam has been found to increase striatal dopamine concentrations in rat studies, whereas lorazepam does not show this effect (<xref ref-type="bibr" rid="bibr29-0004867411432074">Bentue-Ferrer et al., 2001</xref>), suggesting that alprazolam may have a unique ability to interact with mesolimbic dopamine reward pathways. Behavioural reward is contingent on timing of the reward stimulus, with proximal stimuli consistently overriding distal ones. Most individuals, for example, associate the dentist with pain induction not reduction.</p>
<p>Alprazolam shares pharmacokinetic properties that are common to other drugs of abuse: it has a rapid onset and offset of action, high binding affinity and high potency. There are additional psychological factors worthy of consideration to help explain alprazolam addiction. Addiction to a prescription medication is generally considered more socially acceptable than illicit drug use (<xref ref-type="bibr" rid="bibr58-0004867411432074">Hernandez and Nelson, 2010</xref>). In patients who suffer anxiety, there is a pervasive risk of the symptoms of benzodiazepine withdrawal being interpreted as the symptoms of continued affliction with panic attacks (<xref ref-type="bibr" rid="bibr106-0004867411432074">Roy-Byrne and Hommer, 1988</xref>).</p>
</sec>
<sec id="section9-0004867411432074">
<title>The difficulty of differentiating withdrawal from rebound or recurrence</title>
<p>Withdrawal from benzodiazepines includes the symptoms of ‘worse anxiety, insomnia and restlessness’ (<xref ref-type="bibr" rid="bibr110-0004867411432074">Salzman, 1991</xref>). Alprazolam, due to its short half-life, also induces inter-dose rebound symptoms (rebound anxiety) in many patients, further complicating the monitoring of underlying anxiety versus a drug-induced anxiety.This cyclical rebound anxiety can lead to further dosing of alprazolam. The negative reinforcement provided by alprazolam (in the form of relief of rebound symptoms) can be a powerful mediator of psychological dependence in the patient (<xref ref-type="bibr" rid="bibr64-0004867411432074">Juergens, 1991</xref>).</p>
<p>Patients taking alprazolam effectively experience at least nightly withdrawals due to its short duration of action, and the inter-dose withdrawal effects can mimic or precipitate panic.Therefore, patients can become stuck in a vicious cycle of increased alprazolam use to combat tolerance and at the same time feel more psychologically dependent to the relief provided by alprazolam. Should there be no effective alternative treatment this may be a necessary evil, but with established efficacy of the SSRIs in this patient group, the dependence potential must be regarded as a considerable adverse consequence of the use of alprazolam in the treatment of PD.</p>
</sec>
<sec id="section10-0004867411432074">
<title>The rapidity of onset of tolerance and physical dependence</title>
<p>Physical dependence on benzodiazepines is due to neuroadaptation of the GABA system, resulting in under-activity when benzodiazepine dose is reduced.The onset of dependence is variable and dose related.Data from the Cross-National Collaborative Panic discontinuation study and Alprazolam SR discontinuation study show that approximately 35% of patients show withdrawal symptoms after 8 weeks taking 2 to 10 mg of alprazolam per day (<xref ref-type="bibr" rid="bibr91-0004867411432074">Pecknold, 1993</xref>). There have also been observations of a minority of patients experiencing protracted withdrawals lasting for months after discontinuation (<xref ref-type="bibr" rid="bibr7-0004867411432074">Ashton, 1991</xref>).</p>
</sec>
<sec id="section11-0004867411432074">
<title>Groups at risk of dose escalation</title>
<p>It has been reported that dose escalation usually occurs in patients who also abuse other drugs or alcohol, and appears less likely to occur in patients without these common comorbidities. In a long-term study (mean 2.5 years) of patients with agoraphobia and panic attacks, <xref ref-type="bibr" rid="bibr80-0004867411432074">Nagy et al. (1989)</xref> found that 70% of patients continued alprazolam (60% reduced dose, 5% same dose, 5% increased dose). <xref ref-type="bibr" rid="bibr96-0004867411432074">Pollack et al. (1993)</xref> also found that most patients remained taking alprazolam (78%) but mean dose did not increase.It can be concluded that dose escalation may only be problematic in a minority of patients, but even without dose escalation discontinuation is difficult.</p>
</sec>
<sec id="section12-0004867411432074">
<title>The ease or difficulty of withdrawal</title>
<p>Evidence indicates that alprazolam results in more severe withdrawal symptoms than other benzodiazepines.<xref ref-type="bibr" rid="bibr53-0004867411432074">Fyer et al. (1987)</xref> found that 15 of 17 patients in a case series had recurrence or increase in panic attacks and nine had additional symptoms associated with benzodiazepine withdrawal.Thirteen of the 17 patients did not complete withdrawal within the 4 to 5 week schedule. The incidence of withdrawal reactions can be reduced by tapering more slowly, but a consistent observation is that even with slow tapering, high-potency benzodiazepines are associated with more symptomatic withdrawal (<xref ref-type="bibr" rid="bibr110-0004867411432074">Salzman, 1991</xref>).</p>
</sec>
<sec id="section13-0004867411432074">
<title>Long-term consequences of dependence</title>
<p>Of 142 patients in the long-term (mean 27.5 weeks) arm of the Cross-National Collaborative Panic discontinuation study, only 47.2% were able to discontinue alprazolam treatment.Certainly a proportion of these patients chose to stay on alprazolam due to symptom management but it is possible a proportion of the remaining 52.8% of patients suffer from adverse effects of the medication but are unable to discontinue due to withdrawal symptoms.With evidence emerging for long-term cognitive side effects and lack of comparative efficacy in comorbid depression (<xref ref-type="bibr" rid="bibr30-0004867411432074">Birkenhäger et al., 1995</xref>) the potential harm of patients who are effectively addicted to alprazolam must be considered.</p>
</sec>
<sec id="section14-0004867411432074">
<title>Prescription as a co-administered medication (e.g. as needed ‘PRN’)</title>
<p>A further possible explanation for increased prescription of alprazolam may relate to its use in short-term co-prescription with antidepressants, or prescription on an ‘as needed’ (PRN) basis. The APA (<xref ref-type="bibr" rid="bibr2-0004867411432074">American Psychiatric Association, 2009</xref>) and RANZCP (<xref ref-type="bibr" rid="bibr107-0004867411432074">Royal Australian and New Zealand College of Psychiatrists, 2003</xref>) guidelines suggest such usage may be appropriate, but caution this practice in the context of potential issues related to withdrawal and dependence. The practice of as needed dosing, which could be motivated by efforts to prevent dependence, is also not without its risks. The APA guidelines warns that such practice ‘promotes fluctuating blood levels that may aggravate anxiety’ (<xref ref-type="bibr" rid="bibr2-0004867411432074">American Psychiatric Association, 2009</xref>) and cite evidence suggesting PRN benzodiazepine dosing is associated with worse outcomes in patients receiving cognitive-behavioural therapy (CBT) for PD (<xref ref-type="bibr" rid="bibr134-0004867411432074">Westra et al., 2002</xref>). Rapid relief of distressing symptoms is a potent behavioural reward, which potentially drives repeated use towards later dependence.</p>
</sec>
<sec id="section15-0004867411432074">
<title>Prescription for conditions other than PD (against PBS rules)</title>
<p>Although prescription of alprazolam under PBS rules is limited to PD only, it is possible that prescription is being undertaken in patients without treatment-resistant PD. There is evidence that some Australian doctors prescribe benzodiazepines outside of accepted indications (<xref ref-type="bibr" rid="bibr132-0004867411432074">Webber, 2009</xref>), although further empirical research in this area is lacking. PBS rules are often not concordant with treatment guidelines or the evidence base, with the use of lamotrigine (<xref ref-type="bibr" rid="bibr71-0004867411432074">Malhi et al., 2009a</xref>,<xref ref-type="bibr" rid="bibr72-0004867411432074">b</xref>; <xref ref-type="bibr" rid="bibr83-0004867411432074">ng et al., 2007</xref>) in bipolar disorder being an exemplar and the motivation to help people in distress may override red tape.</p>
</sec></sec>
<sec id="section16-0004867411432074">
<title>The relative effectiveness of alprazolam in PD</title>
<p>Since its initial listing in the late 1970s, multiple short-term clinical trials have been conducted comparing alprazolam to alternative pharmacological agents (placebo, alternative benzodiazepine, TCAs and SSRIs) in the treatment of PD. The main findings are summarised below for each comparative group.</p>
<sec id="section17-0004867411432074">
<title>Alprazolam vs. placebo for PD</title>
<p>Alprazolam’s superior short-term efficacy over placebo was demonstrated in numerous controlled clinical trials performed between 1980 and the early 1990s (<xref ref-type="bibr" rid="bibr42-0004867411432074">Chouinard et al., 1982</xref>; <xref ref-type="bibr" rid="bibr51-0004867411432074">Evans, 1981</xref>). Meta-analyses (<xref ref-type="bibr" rid="bibr32-0004867411432074">Boyer, 1995</xref>; <xref ref-type="bibr" rid="bibr45-0004867411432074">Cox et al., 1992</xref>) of the known controlled trials of alprazolam demonstrated clear advantage in reduction of panic symptoms.The first and second Cross-National Collaborative Panic Studies (CNCPS) (<xref ref-type="bibr" rid="bibr21-0004867411432074">Ballenger et al., 1988</xref>; <xref ref-type="bibr" rid="bibr47-0004867411432074">Cross-National Collaborative Panic Study SPI, 1992</xref>; <xref ref-type="bibr" rid="bibr85-0004867411432074">Noyes et al., 1988</xref>) remain the largest randomised placebo-controlled trials of alprazolam use in PD. The first CNCPS (<xref ref-type="bibr" rid="bibr21-0004867411432074">Ballenger et al., 1988</xref>; <xref ref-type="bibr" rid="bibr67-0004867411432074">Klerman, 1988</xref>; <xref ref-type="bibr" rid="bibr85-0004867411432074">Noyes et al., 1988</xref>; <xref ref-type="bibr" rid="bibr92-0004867411432074">Pecknold et al., 1988</xref>) randomised over 500 patients from Australia, the USA and Canada with DSM-III criteria agoraphobia with panic attacks or PD into alprazolam (flexible dosing to reach 6 mg daily in 3 weeks) or placebo groups for 8 weeks. Outcome measurements assessing anxiety, global improvement, panic attacks and anticipatory anxiety episodes demonstrated a significant advantage to alprazolam over placebo at 4 weeks. However, completer analysis at 8 weeks demonstrated no significant advantage to alprazolam in frequency of panic attacks and more moderate effects in other domains (<xref ref-type="bibr" rid="bibr21-0004867411432074">Ballenger et al., 1988</xref>). In addition, the improvement attributable to alprazolam reversed in many patients after drug withdrawal (<xref ref-type="bibr" rid="bibr92-0004867411432074">Pecknold et al., 1988</xref>). This finding is similar to studies with other agents (SSRIs) in PD that demonstrate high relapse rates after treatment cessation (<xref ref-type="bibr" rid="bibr74-0004867411432074">Mavissakalian and Perel, 2002</xref>; <xref ref-type="bibr" rid="bibr127-0004867411432074">Toni et al., 2000</xref>). A major issue with this trial was patient drop-out, most notably in the placebo arm, which has led to debate over the validity of these results (<xref ref-type="bibr" rid="bibr73-0004867411432074">Marks et al., 1989</xref>). However, given the large number of controlled trials supporting efficacy of alprazolam in controlling symptoms of PD (<xref ref-type="bibr" rid="bibr5-0004867411432074">Andersch et al., 1991</xref>; <xref ref-type="bibr" rid="bibr48-0004867411432074">Curtis et al., 1993</xref>) the WFSBP guidelines have attributed it with category A evidence (‘full evidence from controlled studies’) (<xref ref-type="bibr" rid="bibr26-0004867411432074">Bandelow et al., 2008</xref>) for PD treatment.</p>
</sec>
<sec id="section18-0004867411432074">
<title>Alprazolam vs. TCAs for PD</title>
<p>Most head-to-head trials involving alprazolam in PD have utilised the TCAs, notably imipramine (<xref ref-type="bibr" rid="bibr40-0004867411432074">Charney et al., 1986</xref>; <xref ref-type="bibr" rid="bibr47-0004867411432074">Cross-National Collaborative Panic Study SPI, 1992</xref>; <xref ref-type="bibr" rid="bibr100-0004867411432074">Rizley et al., 1986</xref>) as comparator. The CNCPS-II study (<xref ref-type="bibr" rid="bibr42-0004867411432074">Cross-National Collaborative Panic Study SPI, 1992</xref>) randomised 1168 patients from 12 study centres with a lifetime diagnosis of DSM-III criteria PD for 8 weeks into placebo, alprazolam and imipramine groups. Dosage was titrated flexibly aiming to reach 6 mg of alprazolam and 150 mg of imipramine daily by 3 weeks. Patients were assessed on multiple outcome measures including ‘overall clinical efficacy and improvement’, ‘panic anxiety’, ‘phobias’, ‘anxiety’ and ‘social functioning’ (<xref ref-type="bibr" rid="bibr42-0004867411432074">Cross-National Collaborative Panic Study SPI, 1992</xref>). Alprazolam and imipramine demonstrated efficacy in most measured domains over placebo. The benefit of alprazolam appeared earlier (1–2 weeks) than imipramine (4 weeks) with both drugs exhibiting similar responses at week 8. A significant placebo response was observed in some outcomes. Similar to the CNCPS-I trial, many alprazolam patients experienced rebound anxiety and withdrawal symptoms after drug discontinuation (<xref ref-type="bibr" rid="bibr1-0004867411432074">Abelson and Curtis, 1993</xref>; <xref ref-type="bibr" rid="bibr53-0004867411432074">Fyer et al., 1987</xref>; <xref ref-type="bibr" rid="bibr86-0004867411432074">Noyes et al., 1991</xref>; <xref ref-type="bibr" rid="bibr88-0004867411432074">O’Sullivan et al., 1994</xref>; <xref ref-type="bibr" rid="bibr92-0004867411432074">Pecknold et al., 1988</xref>), although patients assigned alprazolam exhibited less discontinuation due to side effects than those taking TCAs.</p>
<p>Over the longer term, there is in addition some evidence supporting alprazolam as being more efficacious than imipramine in controlling panic symptoms (<xref ref-type="bibr" rid="bibr99-0004867411432074">Rickels and Schweizer, 1998</xref>), although outcomes from another long-term follow-up (<xref ref-type="bibr" rid="bibr4-0004867411432074">Andersch and Hetta, 2003</xref>) did not replicate this finding.</p>
</sec>
<sec id="section19-0004867411432074">
<title>Alprazolam vs. alternative benzodiazepines for PD</title>
<p>Controlled trials in PD have compared alprazolam to the benzodiazepines diazepam (<xref ref-type="bibr" rid="bibr50-0004867411432074">Dunner et al., 1986</xref>; <xref ref-type="bibr" rid="bibr84-0004867411432074">Noyes et al., 1996</xref>), clonazepam (<xref ref-type="bibr" rid="bibr49-0004867411432074">Davidson and Moroz, 1998</xref>; <xref ref-type="bibr" rid="bibr57-0004867411432074">Herman et al., 1987</xref>; <xref ref-type="bibr" rid="bibr105-0004867411432074">Rosenbaum et al., 1997</xref>; <xref ref-type="bibr" rid="bibr125-0004867411432074">Tesar et al., 1987</xref>, <xref ref-type="bibr" rid="bibr126-0004867411432074">1991</xref>), lorazepam (<xref ref-type="bibr" rid="bibr39-0004867411432074">Charney and Woods, 1989</xref>; <xref ref-type="bibr" rid="bibr111-0004867411432074">Schweizer et al., 1988</xref>, <xref ref-type="bibr" rid="bibr112-0004867411432074">1990</xref>), etizolam (<xref ref-type="bibr" rid="bibr75-0004867411432074">Meco et al., 1989</xref>) and adinazolam (<xref ref-type="bibr" rid="bibr97-0004867411432074">Pyke and Greenberg, 1989</xref>).In general these trials failed to demonstrate superiority of alprazolam over alternate benzodiazepine in the management of PD symptoms or in clinical tolerability. A recent meta-analysis of controlled clinical trials found no significant advantage of alprazolam over comparator benzodiazepine (<xref ref-type="bibr" rid="bibr78-0004867411432074">Moylan et al., 2011</xref>) across measured domains in PD treatment.</p>
</sec>
<sec id="section20-0004867411432074">
<title>Alprazolam vs. SSRIs for PD</title>
<p>Multiple clinical trials and meta-analysis have found SSRIs to have equivalent efficacy but better tolerability to TCAs (<xref ref-type="bibr" rid="bibr6-0004867411432074">Anderson, 2000</xref>; <xref ref-type="bibr" rid="bibr16-0004867411432074">Bakker et al., 2000</xref>, <xref ref-type="bibr" rid="bibr17-0004867411432074">2002</xref>, <xref ref-type="bibr" rid="bibr18-0004867411432074">2005</xref>; <xref ref-type="bibr" rid="bibr90-0004867411432074">Otto et al., 2001</xref>).Only one trial (<xref ref-type="bibr" rid="bibr109-0004867411432074">Saida and Svjetlana, 2005</xref>) directly comparing alprazolam and an SSRI (sertraline) has been published to date to our knowledge. In this study, sertraline 50 mg was compared with alprazolam (1–1.5 mg/day) in a small group of randomised outpatients with PD. No difference in outcomes was found between sertraline and alprazolam in broad measures of anxiety (Hamilton Anxiety Rating Scale, HAM-A) and agoraphobia over 6 weeks. A meta-analysis comparing the efficacy of SSRIs to imipramine (150 mg/day), alprazolam (4 mg/day) and placebo demonstrated superiority for SSRIs in control of panic symptoms (<xref ref-type="bibr" rid="bibr32-0004867411432074">Boyer, 1995</xref>), with this result less pronounced in trials with larger mean doses of alprazolam and TCAs. Another meta-analysis performed in 2005 (<xref ref-type="bibr" rid="bibr76-0004867411432074">Mitte, 2005</xref>), however, failed to demonstrate significant differences between the efficacy of benzodiazepines (grouped), TCAs and SSRIs.</p>
</sec></sec>
<sec id="section21-0004867411432074">
<title>Important considerations from efficacy literature</title>
<p>An important consideration in the alprazolam efficacy literature is the choice of outcome measures utilised. The majority of studies involving alprazolam utilised broad measures of PD severity (e.g. HAM-A, counts of panic attack frequency, global impression scales) in assessing efficacy. Such measures lack the advantages of specific ratings scales for PD, e.g. Panic and Agoraphobia Scale (P&amp;A) (<xref ref-type="bibr" rid="bibr24-0004867411432074">Bandelow et al., 1998</xref>) and Panic Disorder Severity Scale (PDSS) (<xref ref-type="bibr" rid="bibr118-0004867411432074">Shear et al., 1997</xref>) that measure multiple domains of PD symptomatology and have greater sensitivity in detecting placebo–drug differences in PD. The predominant use of broad measures versus specific PD rating scales in the alprazolam studies may not provide the most reliable evidence of its overall treatment effect in PD, specifically in domains not associated with panic attacks (e.g. quality of life) (<xref ref-type="bibr" rid="bibr25-0004867411432074">Bandelow et al., 2007</xref>), making comparisons to newer treatments (e.g. SSRIs) assessed on these domains more difficult.</p>
</sec>
<sec id="section22-0004867411432074">
<title>Tolerability of alprazolam in the short and long term</title>
<sec id="section23-0004867411432074">
<title>Short-term side effects and tolerability</title>
<p>Alprazolam exhibits a similar side-effect profile to other benzodiazepines (<xref ref-type="bibr" rid="bibr21-0004867411432074">Ballenger et al., 1988</xref>; <xref ref-type="bibr" rid="bibr88-0004867411432074">O’Sullivan et al., 1994</xref>; <xref ref-type="bibr" rid="bibr129-0004867411432074">Verster and Volkerts, 2004</xref>). An investigation of adverse effects recorded in the CNCPS II trial (<xref ref-type="bibr" rid="bibr37-0004867411432074">Cassano et al., 1994</xref>) demonstrated significantly increased rates of sedation (44% vs. 16%), fatigue/weakness (18% vs. 12%) and memory problems (15% vs. 9%) (<xref ref-type="bibr" rid="bibr37-0004867411432074">Cassano et al., 1994</xref>) with alprazolam over placebo at week 4. Other reviews (<xref ref-type="bibr" rid="bibr63-0004867411432074">Jonas and Cohon, 1993</xref>) and reports from major studies (<xref ref-type="bibr" rid="bibr21-0004867411432074">Ballenger et al., 1988</xref>; <xref ref-type="bibr" rid="bibr88-0004867411432074">O’Sullivan et al., 1994</xref>) also report significant side effects with alprazolam use including irritability, poor concentration, slurred speech, decreased appetite and weight loss. Alprazolam can lead to rebound insomnia, with rapid tolerance developed to short-term sleep-inducing effects (<xref ref-type="bibr" rid="bibr65-0004867411432074">Kales et al., 1987</xref>). Most side effects were most prominent early in treatment, decreased throughout treatment courses but were maintained above placebo in long-term studies (<xref ref-type="bibr" rid="bibr4-0004867411432074">Andersch and Hetta, 2003</xref>, <xref ref-type="bibr" rid="bibr96-0004867411432074">Pollack et al., 1993</xref>; <xref ref-type="bibr" rid="bibr99-0004867411432074">Rickels and Schweizer, 1998</xref>).</p>
</sec>
<sec id="section24-0004867411432074">
<title>Rebound anxiety and withdrawal symptoms</title>
<p>Rebound anxiety and withdrawal symptoms are clinically significant issues with the use of alprazolam (<xref ref-type="bibr" rid="bibr129-0004867411432074">Verster and Volkerts, 2004</xref>) and have been discussed at length previously. Rebound anxiety and inter-dose symptom return are common with discontinuation of alprazolam (<xref ref-type="bibr" rid="bibr5-0004867411432074">Andersch et al., 1991</xref>; <xref ref-type="bibr" rid="bibr53-0004867411432074">Fyer et al., 1987</xref>; <xref ref-type="bibr" rid="bibr91-0004867411432074">Pecknold, 1993</xref>; <xref ref-type="bibr" rid="bibr92-0004867411432074">Pecknold et al., 1988</xref>), and appear to occur more often than with other benzodiazepines (<xref ref-type="bibr" rid="bibr135-0004867411432074">Wolf and Griffiths, 1991</xref>). Rebound anxiety, issues with withdrawal syndromes and physiological dependence ‘appears to be greater among patients taking benzodiazepines with short-to-intermediate elimination half-lives’ (<xref ref-type="bibr" rid="bibr41-0004867411432074">Chouinard, 2004</xref>). Alprazolam demonstrates a short half-life, a high binding affinity to the GABA receptor and a rapid onset and offset of action, properties that are associated with greater risk of dependency and withdrawal (<xref ref-type="bibr" rid="bibr87-0004867411432074">O’Brien, 2005</xref>).</p>
</sec>
<sec id="section25-0004867411432074">
<title>Longer-term side effects</title>
<p>Chronic alprazolam use is associated with long-term adverse effects (<xref ref-type="bibr" rid="bibr129-0004867411432074">Verster and Volkerts, 2004</xref>) on memory (<xref ref-type="bibr" rid="bibr69-0004867411432074">Leufkens et al., 2007</xref>; <xref ref-type="bibr" rid="bibr128-0004867411432074">Vermeeren et al., 1995</xref>; <xref ref-type="bibr" rid="bibr130-0004867411432074">Verster et al., 2002</xref>), driving ability (<xref ref-type="bibr" rid="bibr69-0004867411432074">Leufkens et al., 2007</xref>; <xref ref-type="bibr" rid="bibr98-0004867411432074">Rapoport et al., 2009</xref>; <xref ref-type="bibr" rid="bibr128-0004867411432074">Vermeeren et al., 1995</xref>) and psychomotor performance (<xref ref-type="bibr" rid="bibr69-0004867411432074">Leufkens et al., 2007</xref>; <xref ref-type="bibr" rid="bibr128-0004867411432074">Vermeeren et al., 1995</xref>). The level of memory impairment produced by benzodiazepines appears to be related to a higher relative lipid solubility and affinity at benzodiazepine receptor (<xref ref-type="bibr" rid="bibr41-0004867411432074">Chouinard, 2004</xref>). Alprazolam exhibits both high relative lipid solubility and high binding affinity.</p>
</sec></sec>
<sec id="section26-0004867411432074">
<title>Wider issues with alprazolam</title>
<sec id="section27-0004867411432074">
<title>Abuse potential and non-clinical effects</title>
<p>Probably as a consequence of its high potency, rapid onset and short half-life (<xref ref-type="bibr" rid="bibr41-0004867411432074">Chouinard, 2004</xref>; <xref ref-type="bibr" rid="bibr79-0004867411432074">Mumford et al., 1995</xref>; <xref ref-type="bibr" rid="bibr135-0004867411432074">Wolf and Griffiths, 1991</xref>), alprazolam has become a drug of abuse (<xref ref-type="bibr" rid="bibr52-0004867411432074">Forrester, 2006</xref>; <xref ref-type="bibr" rid="bibr123-0004867411432074">Substance Abuse and Mental Health Services Administration, 2010</xref>). Discussion regarding the potential for alprazolam to induce dependence is found earlier in the review. Some researchers suggest continuing use of alprazolam (<xref ref-type="bibr" rid="bibr11-0004867411432074">Australian Bureau of Statistics, 2010</xref>; <xref ref-type="bibr" rid="bibr116-0004867411432074">SDI/Verispan, 2010</xref>) may represent ongoing clinical management of chronic conditions rather than drug dependence (<xref ref-type="bibr" rid="bibr101-0004867411432074">Romach et al., 1991</xref>, <xref ref-type="bibr" rid="bibr102-0004867411432074">1992</xref>; <xref ref-type="bibr" rid="bibr117-0004867411432074">Sellers et al., 1993</xref>). A qualitative investigation of youth attitudes concerning alprazolam revealed use was deemed common, the drug was highly addictive, difficult to cease and medical professionals were the greatest facilitators of use (<xref ref-type="bibr" rid="bibr94-0004867411432074">Peters et al., 2007</xref>), indicating that at least a portion of ongoing use may relate to drug dependence.</p>
<p>Alprazolam is a common drug in overdose incidents leading to emergency department admissions (<xref ref-type="bibr" rid="bibr35-0004867411432074">Buukx et al., 2010</xref>; <xref ref-type="bibr" rid="bibr123-0004867411432074">Substance Abuse and Mental Health Services Administration, 2010</xref>). Data from the US Substance Abuse and Mental Health Services Administration (SAMHSA) showed that alprazolam is the most common benzodiazepine involved in emergency overdose situations, both in isolation and mixed with alcohol and other substances (<xref ref-type="bibr" rid="bibr123-0004867411432074">Substance Abuse and Mental Health Services Administration, 2010</xref>). These data also suggest the incidence of alprazolam events is increasing at a faster rate than other benzodiazepines, from approximately 46,000 in 2004 to 80,000 in 2008 (73% increase) (<xref ref-type="bibr" rid="bibr123-0004867411432074">Substance Abuse and Mental Health Services Administration, 2010</xref>). This finding may relate to the fact that alprazolam is the most utilised benzodiazepine in the US population.In an Australian study of emergency department visits, the majority of alprazolam used in overdose was obtained through doctor prescription (<xref ref-type="bibr" rid="bibr35-0004867411432074">Buukx et al., 2010</xref>). This high use of alprazolam in overdose is noteworthy, as in such situations alprazolam has demonstrated greater toxicity than other benzodiazepines with patients in one study 2.06 times more likely to require treatment in an intensive care unit than other benzodiazepines after adjusting for age, dose, gender and co-administered drugs (<xref ref-type="bibr" rid="bibr62-0004867411432074">Isbister et al., 2004</xref>). It should be noted, however, that in overdose alprazolam (like other benzodiazepines) may be safer than other medications utilised for PD (e.g. TCAs).</p>
<p>The impact of benzodiazepines on driving ability is a controversial area. In a study testing driving ability of 20 health volunteers administered alprazolam 1 mg, six of the subjects demonstrated impairment to the point of unsafe driving (<xref ref-type="bibr" rid="bibr130-0004867411432074">Verster et al., 2002</xref>). Acute administration of alprazolam 1 mg has been equated to a blood alcohol concentration of 0.15% (<xref ref-type="bibr" rid="bibr129-0004867411432074">Verster and Volkerts, 2004</xref>), significantly higher than most country legal limits, although whether use is causally related to road traffic accidents is disputed (<xref ref-type="bibr" rid="bibr27-0004867411432074">Barbone et al., 1998</xref>; <xref ref-type="bibr" rid="bibr122-0004867411432074">Smink et al., 2010</xref>). Benzodiazepines are commonly found in blood samples taken from drivers involved in major trauma accidents in Australia (15.6%) (<xref ref-type="bibr" rid="bibr38-0004867411432074">Ch’ng et al., 2007</xref>) or apprehended due to dangerous or erratic driving in Norway (46.2%) (<xref ref-type="bibr" rid="bibr43-0004867411432074">Christophersen and Morland, 2008</xref>). Recent data from individuals involved in car accidents in Victoria (July 2009 to July 2010) found that all of those with alprazolam in their blood were responsible for the collision (<xref ref-type="bibr" rid="bibr89-0004867411432074">Ogden et al., 2010</xref>).This data also demonstrated that alprazolam levels found in patients were well above those expected from therapeutic dosing, with the mean level 0.138 mg/L in the toxic range (<xref ref-type="bibr" rid="bibr89-0004867411432074">Ogden et al., 2010</xref>). This probably indicates this group of patients were using alprazolam outside of normal prescribing patterns potentially indicative of an abuse pattern. Impairment of motor coordination occurs in a dose-dependent fashion and hence care should be undertaken with driving when changes or initiation of benzodiazepines has occurred.</p>
</sec></sec>
<sec id="section28-0004867411432074">
<title>What is the role for alprazolam in the future of PD treatment?</title>
<p>Alprazolam is without doubt the most investigated benzodiazepine in the treatment of PD and consideration of its place in future treatment should be made in this context. However, the available comparative evidence does not suggest that alprazolam confers an advantage over other benzodiazepines in PD treatment (<xref ref-type="bibr" rid="bibr78-0004867411432074">Moylan et al., 2011</xref>) and it may potentially have more pronounced adverse effects owing to its high potency and short half-life. There are currently 11 different benzodiazepines in oral preparations available within Australia, with at least 28 different trade versions (<xref ref-type="bibr" rid="bibr15-0004867411432074">Australian Government Department of Health and Ageing, 2011</xref>). Probably the best comparator benzodiazepine is clonazepam (<xref ref-type="bibr" rid="bibr104-0004867411432074">Rosenbaum, 2004</xref>), owing to its high potency but longer half-life (<xref ref-type="bibr" rid="bibr46-0004867411432074">Crevoisier et al., 2003</xref>), and it may potentially mitigate some of the problems associated with alprazolam use including inter-dose anxiety and strong withdrawal phenomenon (<xref ref-type="bibr" rid="bibr57-0004867411432074">Herman et al., 1987</xref>). Some studies have demonstrated successful discontinuation of clonazepam if achieved through a gradual taper (<xref ref-type="bibr" rid="bibr77-0004867411432074">Moroz and Rosenbaum, 1999</xref>; <xref ref-type="bibr" rid="bibr81-0004867411432074">Nardi et al., 2010</xref>). In addition, a randomised controlled trial investigating potential strategies for managing PD refractory to initial treatment utilised clonazepam as augmentation to sertraline (after non-response to sertraline only or secondary dose increase) and found no difference in augmentation versus institution of CBT on a variety of panic scales (<xref ref-type="bibr" rid="bibr120-0004867411432074">Simon et al., 2009</xref>).</p>
<p>Inappropriate prescription of a medication is more likely to occur where prescribers have less experience or familiarity with the appropriate use of the drug and knowledge of available alternatives. Given alprazolam has only a narrowly defined supported indication under the PBS, and limited indication in the treatment of PD in clinical practice guidelines, it is possible a lack of familiarity with treatment guidelines is contributing to inappropriate use. High rates of alprazolam use and diversion were recently targeted in Tasmania through a combination of education campaigns and new restrictions on prescribing (<xref ref-type="bibr" rid="bibr54-0004867411432074">Galloway, 2007</xref>; <xref ref-type="bibr" rid="bibr60-0004867411432074">Hooper et al., 2009</xref>). A 12-month follow-up of this effort demonstrated a 15.4% reduction in alprazolam prescriptions over the year, in contrast to a 1.3% increase in prescriptions throughout the rest of Australia (<xref ref-type="bibr" rid="bibr60-0004867411432074">Hooper et al., 2009</xref>). Such moves could be distributed more widely in an effort to decrease potentially inappropriate prescriptions. It is however not known to what extent alprazolam is misused. The ‘total consumption model’ may have validity in predicting rates of misuse in alprazolam. In this model, the proportion of individuals with excessive use (misuse) of a substance (e.g. alcohol) increases as the overall average population consumption increases (<xref ref-type="bibr" rid="bibr121-0004867411432074">Skog and Rossow, 2006</xref>). Although classically described in alcohol (<xref ref-type="bibr" rid="bibr121-0004867411432074">Skog and Rossow, 2006</xref>) and gambling behaviours (<xref ref-type="bibr" rid="bibr55-0004867411432074">Hansen and Rossow, 2008</xref>), the model was recently tested in the use of prescription medicine carisoprodol in the Norwegian general population. Results suggested that the rate of excessive carisoprodol use was highly correlated with the quantity of carisoprodol dispensed (<xref ref-type="bibr" rid="bibr33-0004867411432074">Bramness and Rossow, 2010</xref>). It is not currently known if the same association is present for use of alprazolam, but if confirmed, would suggest that increasing prescription and utilisation are potentially associated with an increased incidence of medication misuse.</p>
</sec>
<sec id="section29-0004867411432074" sec-type="conclusions">
<title>Conclusion</title>
<p>The current place of alprazolam in treatment of PD in Australia merits renewed consideration. Further research into how alprazolam is used by patients, to what extent prescription rates reflect actual medication consumption, and into the rates of alprazolam diversion (e.g. illicit use) is required. Further, the development of best-practice strategies for managing treatment-refractory PD with subsequent integration into clinical practice guidelines would assist prescribers in managing this population of patients. Such guidelines could provide information about the relative effectiveness of less studied but widely utilised benzodiazepine alternatives (e.g. diazepam) for PD treatment and where short-acting benzodiazepines such as alprazolam or lorazepam may be most appropriate (e.g. in short-term or PRN use). This work would assist in determining what place alprazolam has in the future of Australian PD treatment.</p>
</sec>
</body>
<back>
<sec id="section30-0004867411432074">
<title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.</p>
</sec>
<sec id="section31-0004867411432074">
<title>Declaration of interest</title>
<p>SM, FG and TN declare no conflicts related to the production of this manuscript.</p>
<p>MB has received Grant/Research Support from Stanley Medical Research Foundation, MBF, NHMRC, Beyond Blue, Geelong Medical Research Foundation, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Organon, Novartis, Mayne Pharma and Servier, has been a speaker for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck, Merck, Pfizer, Sanofi Synthelabo, Servier, Solvayand Wyeth, and served as a consultant to Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck and Servier.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Abelson</surname><given-names>JL</given-names></name>
<name><surname>Curtis</surname><given-names>GC</given-names></name>
</person-group> (<year>1993</year>) <article-title>Discontinuation of alprazolam after successful treatment of panic disorder: A naturalistic follow-up study</article-title>. <source>Journal of Anxiety Disorders</source> <volume>7</volume>: <fpage>107</fpage>–<lpage>117</lpage>.</citation>
</ref>
<ref id="bibr2-0004867411432074">
<citation citation-type="book">
<collab>American Psychiatric Association</collab> (<year>2009</year>) <source>Practice Guideline for the Treatment of Patients with Panic Disorder</source>, <edition>2nd edn.</edition> <publisher-loc>Washington DC</publisher-loc>: <publisher-name>APA</publisher-name>.</citation>
</ref>
<ref id="bibr3-0004867411432074">
<citation citation-type="journal">
<collab>American Psychiatric Association, Work Group on Panic Disorder</collab> (<year>1998</year>) <article-title>Practice guideline for the treatment of patients with panic disorder</article-title>. <source>American Journal of Psychiatry</source> <volume>155</volume>: <fpage>1</fpage>–<lpage>34</lpage>.</citation>
</ref>
<ref id="bibr4-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Andersch</surname><given-names>S</given-names></name>
<name><surname>Hetta</surname><given-names>J</given-names></name>
</person-group> (<year>2003</year>) <article-title>A 15-year follow-up study of patients with panic disorder</article-title>. <source>European Psychiatry</source> <volume>18</volume>: <fpage>401</fpage>–<lpage>408</lpage>.</citation>
</ref>
<ref id="bibr5-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Andersch</surname><given-names>S</given-names></name>
<name><surname>Rosenberg</surname><given-names>N</given-names></name>
<name><surname>Kullingsjo</surname><given-names>H</given-names></name><etal/>
</person-group>. (<year>1991</year>) <article-title>Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter study</article-title>. <source>Acta Psychiatrica Scandinavica</source> <volume>83</volume>: <fpage>18</fpage>–<lpage>27</lpage>.</citation>
</ref>
<ref id="bibr6-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Anderson</surname><given-names>I</given-names></name>
</person-group> (<year>2000</year>) <article-title>Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta analysis of efficacy and tolerability</article-title>. <source>Journal of Affective Disorders</source> <volume>58</volume>: <fpage>19</fpage>–<lpage>36</lpage>.</citation>
</ref>
<ref id="bibr7-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ashton</surname><given-names>H</given-names></name>
</person-group> (<year>1991</year>) <article-title>Protracted withdrawal syndromes from benzodiazepines</article-title>. <source>Journal of Substance Abuse Treatment</source> <volume>8</volume>: <fpage>19</fpage>–<lpage>28</lpage>.</citation>
</ref>
<ref id="bibr8-0004867411432074">
<citation citation-type="book">
<collab>Australian Bureau of Statistics</collab> (<year>1997</year>) <source>Mental Health and Wellbeing: Profile of Adults, Australia, 1997</source>. <publisher-loc>Canberra, ACT</publisher-loc>: <publisher-name>Commonwealth Government of Australia</publisher-name>.</citation>
</ref>
<ref id="bibr9-0004867411432074">
<citation citation-type="book">
<collab>Australian Bureau of Statistics</collab> (<year>2007a</year>) <source>National Survey of Mental Health and Wellbeing: Summary of Results, 2007</source>. <publisher-loc>Canberra, ACT</publisher-loc>: <publisher-name>Commonwealth Government of Australia</publisher-name>.</citation>
</ref>
<ref id="bibr10-0004867411432074">
<citation citation-type="gov">
<collab>Australian Bureau of Statistics</collab> (<year>2007b</year>) <source>National Survey of Mental Health and Wellbeing: Summary of Results, 2007. Appendix 2: Comparison between 1997 and 2007</source>. <publisher-loc>Canberra, ACT</publisher-loc>: <publisher-name>Commonwealth Government of Australia</publisher-name>. <comment>Available at: <ext-link ext-link-type="uri" xlink:href="http://www.abs.gov.au/ausstats/abs@.nsf/Products/4326.0~2007~Appendix~Comparison+between+1997+and+2007+(Appendix)?OpenDocument#1421131413109948">www.abs.gov.au/ausstats/abs@.nsf/Products/4326.0~2007~Appendix~Comparison+between+1997+and+2007+(Appendix)?OpenDocument#1421131413109948</ext-link></comment></citation>
</ref>
<ref id="bibr11-0004867411432074">
<citation citation-type="book">
<collab>Australian Bureau of Statistics</collab> (<year>2010</year>) <source>Pharmaceutical Benefits Scheme, Statistics</source>. <publisher-loc>Canberra, ACT</publisher-loc>: <publisher-name>Commonwealth Government of Australia</publisher-name>.</citation>
</ref>
<ref id="bibr12-0004867411432074">
<citation citation-type="book">
<collab>Australian Government Department of Health and Ageing</collab> (<year>1997</year>) <source>Australian Statistics on Medicines</source>. <publisher-loc>Woden, ACT</publisher-loc>: <publisher-name>Department of Health and Ageing</publisher-name>.</citation>
</ref>
<ref id="bibr13-0004867411432074">
<citation citation-type="gov">
<collab>Australian Government Department of Health and Ageing</collab> (<year>2008</year>) <source>Australian Statistics on Medicines</source>. <publisher-loc>Woden</publisher-loc>: <publisher-name>ACT, Department of Health and Ageing</publisher-name>. <comment>Available at <ext-link ext-link-type="uri" xlink:href="http://www.health.gov.au/internet/main/publishing.nsf/content/health-pbs-general-pubs-asm.htm">www.health.gov.au/internet/main/publishing.nsf/content/health-pbs-general-pubs-asm.htm</ext-link></comment> (<access-date>accessed 12 August 2011</access-date>).</citation>
</ref>
<ref id="bibr14-0004867411432074">
<citation citation-type="book">
<collab>Australia Government Department of Health and Ageing</collab> (<year>2010</year>) <source>Medicare Australia Statistics: PBS&amp;RPBS Items 2130D, 2131E, 2132F, 8188G</source>. <publisher-loc>Canberra, ACT</publisher-loc>: <publisher-name>Commonwealth Government of Australia</publisher-name>.</citation>
</ref>
<ref id="bibr15-0004867411432074">
<citation citation-type="book">
<collab>Australian Government Department of Health and Ageing</collab> (<year>2011</year>) <source>Schedule of Pharmaceutical Benefits</source>. <publisher-loc>Canberra, ACT</publisher-loc>: <publisher-name>Department of Health and Ageing</publisher-name>.</citation>
</ref>
<ref id="bibr16-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bakker</surname><given-names>A</given-names></name>
<name><surname>van Balkom</surname><given-names>A</given-names></name>
<name><surname>van Dyck</surname><given-names>R</given-names></name>
</person-group> (<year>2000</year>) <article-title>Selective serotonin reuptake inhibitors in the treatment of panic disorder and agoraphobia</article-title>. <source>International Clinical Psychopharmacology</source> <volume>15</volume>: <fpage>S25</fpage>–<lpage>30</lpage>.</citation>
</ref>
<ref id="bibr17-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bakker</surname><given-names>A</given-names></name>
<name><surname>van Balkom</surname><given-names>A</given-names></name>
<name><surname>Spinhoven</surname><given-names>P</given-names></name>
</person-group> (<year>2002</year>) <article-title>SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis</article-title>. <source>Acta Psychiatrica Scandinavica</source> <volume>106</volume>: <fpage>163</fpage>–<lpage>167</lpage>.</citation>
</ref>
<ref id="bibr18-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bakker</surname><given-names>A</given-names></name>
<name><surname>van Balkom</surname><given-names>A</given-names></name>
<name><surname>Stein</surname><given-names>D</given-names></name>
</person-group> (<year>2005</year>) <article-title>Evidence-based pharmacotherapy of panic disorder</article-title>. <source>International Journal of Neuropsychopharmacology</source> <volume>8</volume>: <fpage>473</fpage>–<lpage>482</lpage>.</citation>
</ref>
<ref id="bibr19-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Balestrieri</surname><given-names>M</given-names></name>
<name><surname>Ruggeri</surname><given-names>M</given-names></name>
<name><surname>Bellantuono</surname><given-names>C</given-names></name>
</person-group> (<year>1989</year>) <article-title>Drug treatment of panic disorder – A critical review of controlled clinical trials</article-title> <source>Psychiatric Developments</source> <volume>7</volume>: <fpage>337</fpage>–<lpage>350</lpage>.</citation>
</ref>
<ref id="bibr20-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ballenger</surname><given-names>J</given-names></name>
</person-group> (<year>1986</year>) <article-title>Pharmacotherapy of the panic disorders</article-title>. <source>Journal of Clinical Psychiatry</source> <volume>47</volume>: <fpage>27</fpage>–<lpage>32</lpage>.</citation>
</ref>
<ref id="bibr21-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ballenger</surname><given-names>JC</given-names></name>
<name><surname>Burrows</surname><given-names>GD</given-names></name>
<name><surname>DuPont</surname><given-names>RL</given-names></name><etal/>
</person-group>. (<year>1988</year>) <article-title>Alprazolam in panic disorder and agoraphobia: Results from a multicenter trial: I. Efficacy in short-term treatment</article-title>. <source>Archives of General Psychiatry</source> <volume>45</volume>: <fpage>413</fpage>–<lpage>422</lpage>.</citation>
</ref>
<ref id="bibr22-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bandelow</surname><given-names>B</given-names></name>
<name><surname>Ruther</surname><given-names>E</given-names></name>
</person-group> (<year>2004</year>) <article-title>Treatment-resistant panic disorder</article-title>. <source>CNS Spectrums</source> <volume>9</volume>: <fpage>725</fpage>–<lpage>739</lpage>.</citation>
</ref>
<ref id="bibr23-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bandelow</surname><given-names>B</given-names></name>
<name><surname>Behnke</surname><given-names>K</given-names></name>
<name><surname>Lenoir</surname><given-names>S</given-names></name><etal/>
</person-group>. (<year>2004</year>) <article-title>Sertraline versus paroxetine in the treatment of panic disorder: an acute, double-blind noninferiority comparison</article-title>. <source>Journal of Clinical Psychiatry</source> <volume>65</volume>: <fpage>405</fpage>–<lpage>413</lpage>.</citation>
</ref>
<ref id="bibr24-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bandelow</surname><given-names>B</given-names></name>
<name><surname>Brunner</surname><given-names>E</given-names></name>
<name><surname>Broocks</surname><given-names>A</given-names></name><etal/>
</person-group>. (<year>1998</year>) <article-title>The use of the Panic and Agoraphobia Scale in a clinical trial</article-title>. <source>Psychiatric Research</source> <volume>77</volume>: <fpage>43</fpage>–<lpage>49</lpage>.</citation>
</ref>
<ref id="bibr25-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bandelow</surname><given-names>B</given-names></name>
<name><surname>Stein</surname><given-names>D</given-names></name>
<name><surname>Dolberg</surname><given-names>O</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo</article-title>. <source>Pharmacopsychiatry</source> <volume>40</volume>: <fpage>152</fpage>–<lpage>156</lpage>.</citation>
</ref>
<ref id="bibr26-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bandelow</surname><given-names>B</given-names></name>
<name><surname>Zohar</surname><given-names>J</given-names></name>
<name><surname>Hollander</surname><given-names>E</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – First revision (2008)</article-title>. <source>World Journal of Biological Psychiatry</source> <volume>9</volume>: <fpage>248</fpage>–<lpage>312</lpage>.</citation>
</ref>
<ref id="bibr27-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barbone</surname><given-names>F</given-names></name>
<name><surname>McMahon</surname><given-names>A</given-names></name>
<name><surname>Davey</surname><given-names>P</given-names></name><etal/>
</person-group>. (<year>1998</year>) <article-title>Association of road-traffic accidents with benzodiazepine use</article-title>. <source>Lancet</source> <volume>352</volume>: <fpage>1331</fpage>–<lpage>1336</lpage>.</citation>
</ref>
<ref id="bibr28-0004867411432074">
<citation citation-type="gov">
<person-group person-group-type="author">
<name><surname>Belouin</surname><given-names>S</given-names></name>
</person-group> (<year>2008</year>) <article-title>Prescribing trends for opioids, benzodiazepines, amphetamines and barbiturates from 1998–2007</article-title>. In: <person-group person-group-type="editor">
<name><surname>Reuter</surname><given-names>N</given-names></name>
<name><surname>Borders-Hemphill</surname><given-names>V</given-names></name>
<name><surname>Mehta</surname><given-names>H</given-names></name>
</person-group> (eds). <source>Substance Abuse and Mental Health Services Administration: Department of Health and Human Services</source>. <comment>Available at: <ext-link ext-link-type="uri" xlink:href="http://www.nac.samhsa.gov/DTAB/Presentations/Aug08/SeanBelouinDTAB0808.ppt">www.nac.samhsa.gov/DTAB/Presentations/Aug08/SeanBelouinDTAB0808.ppt</ext-link></comment> (<access-date>accessed 30 December 2010</access-date>).</citation>
</ref>
<ref id="bibr29-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bentue-Ferrer</surname><given-names>D</given-names></name>
<name><surname>Reymann</surname><given-names>JM</given-names></name>
<name><surname>Tribut</surname><given-names>O</given-names></name><etal/>
</person-group>. (<year>2001</year>) <article-title>Role of dopaminergic and serotonergic systems on behavioral stimulatory effects of low-dose alprazolam and lorazepam</article-title>. <source>European Neuropsychopharmacology</source> <volume>11</volume>: <fpage>41</fpage>–<lpage>50</lpage>.</citation>
</ref>
<ref id="bibr30-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Birkenhäger</surname><given-names>TK</given-names></name>
<name><surname>Moleman</surname><given-names>P</given-names></name>
<name><surname>Nolen</surname><given-names>WA</given-names></name>
</person-group> (<year>1995</year>) <article-title>Benzodiazepines for depression? A review of the literature</article-title>. <source>International Clinical Psychopharmacology</source> <volume>10</volume>: <fpage>181</fpage>–<lpage>195</lpage>.</citation>
</ref>
<ref id="bibr31-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Black</surname><given-names>DW</given-names></name>
<name><surname>Wesner</surname><given-names>R</given-names></name>
<name><surname>Bowers</surname><given-names>W</given-names></name><etal/>
</person-group>. (<year>1993</year>) <article-title>A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder</article-title>. <source>Archives of General Psychiatry</source> <volume>50</volume>: <fpage>44</fpage>–<lpage>50</lpage>.</citation>
</ref>
<ref id="bibr32-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Boyer</surname><given-names>W</given-names></name>
</person-group> (<year>1995</year>) <article-title>Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis</article-title>. <source>International Clinical Psychopharmacology</source> <volume>10</volume>: <fpage>45</fpage>–<lpage>49</lpage>.</citation>
</ref>
<ref id="bibr33-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bramness</surname><given-names>J</given-names></name>
<name><surname>Rossow</surname><given-names>I</given-names></name>
</person-group> (<year>2010</year>) <article-title>Can the total consumption of a medicinal drug be used as an indicator of excessive use? The case of carisoprodol</article-title>. <source>Drugs: Education, Prevention and Policy</source> <volume>17</volume>: <fpage>168</fpage>–<lpage>180</lpage>.</citation>
</ref>
<ref id="bibr34-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bruce</surname><given-names>SE</given-names></name>
<name><surname>Vasile</surname><given-names>RG</given-names></name>
<name><surname>Goisman</surname><given-names>RM</given-names></name><etal/>
</person-group>. (<year>2003</year>) <article-title>Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia?</article-title> <source>American Journal of Psychiatry</source> <volume>160</volume>: <fpage>1432</fpage>–<lpage>1438</lpage>.</citation>
</ref>
<ref id="bibr35-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Buukx</surname><given-names>P</given-names></name>
<name><surname>Loxley</surname><given-names>W</given-names></name>
<name><surname>Dietze</surname><given-names>P</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Medications used in overdose and how they are acquired – an investigation of cases attending an inner Melbourne emergency department</article-title>. <source>Australian and New Zealand Journal of Public Health</source> <volume>34</volume>: <fpage>401</fpage>–<lpage>404</lpage>.</citation>
</ref>
<ref id="bibr36-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cabana</surname><given-names>MD</given-names></name>
<name><surname>Rand</surname><given-names>CS</given-names></name>
<name><surname>Powe</surname><given-names>NR</given-names></name><etal/>
</person-group>. (<year>1999</year>) <article-title>Why don’t physicians follow clinical practice guidelines? A framework for improvement</article-title>. <source>Journal of the American Medical Association</source> <volume>282</volume>: <fpage>1458</fpage>–<lpage>1465</lpage>.</citation>
</ref>
<ref id="bibr37-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cassano</surname><given-names>G</given-names></name>
<name><surname>Toni</surname><given-names>C</given-names></name>
<name><surname>Petracca</surname><given-names>A</given-names></name><etal/>
</person-group>. (<year>1994</year>) <article-title>Adverse effects associated with the short-term treatment of panic disorder with imipramine, alprazolam or placebo</article-title>. <source>European Neuropsychopharmacology</source> <volume>4</volume>: <fpage>47</fpage>–<lpage>53</lpage>.</citation>
</ref>
<ref id="bibr38-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ch’ng</surname><given-names>CW</given-names></name>
<name><surname>Fitzgerald</surname><given-names>M</given-names></name>
<name><surname>Gerostamoulos</surname><given-names>J</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Drug use in motor vehicle drivers presenting to an Australian, adult major trauma centre</article-title>. <source>Emergency Medicine Australasia</source> <volume>19</volume>: <fpage>359</fpage>–<lpage>365</lpage>.</citation>
</ref>
<ref id="bibr39-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Charney</surname><given-names>DS</given-names></name>
<name><surname>Woods</surname><given-names>SW</given-names></name>
</person-group> (<year>1989</year>) <article-title>Benzodiazepine treatment of panic disorder: a comparison of alprazolam and lorazepam</article-title>. <source>Journal of Clinical Psychiatry</source> <volume>50</volume>: <fpage>418</fpage>–<lpage>423</lpage>.</citation>
</ref>
<ref id="bibr40-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Charney</surname><given-names>D</given-names></name>
<name><surname>Woods</surname><given-names>S</given-names></name>
<name><surname>Goodman</surname><given-names>W</given-names></name><etal/>
</person-group>. (<year>1986</year>) <article-title>Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam and trazodone</article-title>. <source>Journal of Clinical Psychiatry</source> <volume>47</volume>: <fpage>580</fpage>–<lpage>586</lpage>.</citation>
</ref>
<ref id="bibr41-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chouinard</surname><given-names>G</given-names></name>
</person-group> (<year>2004</year>) <article-title>Issues in the clinical use of benzodiazepine: potency, withdrawal, and rebound</article-title>. <source>Journal of Clinical Psychiatry</source> <volume>65</volume>: <fpage>7</fpage>–<lpage>12</lpage>.</citation>
</ref>
<ref id="bibr42-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chouinard</surname><given-names>GF</given-names></name>
<name><surname>Annable</surname><given-names>L</given-names></name>
<name><surname>Fontaine</surname><given-names>R</given-names></name><etal/>
</person-group>. (<year>1982</year>) <article-title>Alprazolam in the treatment of generalized anxiety and panic disorders: a double-blind placebo-controlled study</article-title>. <source>Psychopharmacology</source> <volume>77</volume>: <fpage>229</fpage>–<lpage>233</lpage>.</citation>
</ref>
<ref id="bibr43-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Christophersen</surname><given-names>AS</given-names></name>
<name><surname>Morland</surname><given-names>J</given-names></name>
</person-group> (<year>2008</year>) <article-title>Frequent detection of benzodiazepines in drugged drivers in Norway</article-title>. <source>Traffic Injury Prevention</source> <volume>9</volume>: <fpage>98</fpage>–<lpage>104</lpage>.</citation>
</ref>
<ref id="bibr44-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cowley</surname><given-names>DS</given-names></name>
<name><surname>Ha</surname><given-names>EH</given-names></name>
<name><surname>Roy-Byrne</surname><given-names>PP</given-names></name>
</person-group> (<year>1997</year>) <article-title>Determinants of pharmacologic treatment failure in panic disorder</article-title>. <source>Journal of Clinical Psychiatry</source> <volume>58</volume>: <fpage>555</fpage>–<lpage>561</lpage>.</citation>
</ref>
<ref id="bibr45-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cox</surname><given-names>B</given-names></name>
<name><surname>Endler</surname><given-names>N</given-names></name>
<name><surname>Lee</surname><given-names>P</given-names></name><etal/>
</person-group>. (<year>1992</year>) <article-title>A meta-analysis of treatments for panic disorder with agoraphobia: impramine, alprazolam, and in vivo exposure</article-title>. <source>Journal of Behavior Therapy and Experimental Psychiatry</source> <volume>23</volume>: <fpage>175</fpage>–<lpage>182</lpage>.</citation>
</ref>
<ref id="bibr46-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Crevoisier</surname><given-names>C</given-names></name>
<name><surname>Delisle</surname><given-names>M</given-names></name>
<name><surname>Joseph</surname><given-names>I</given-names></name><etal/>
</person-group>. (<year>2003</year>) <article-title>Comparative single-dose pharmacokinetics of clonazepam following intravenous, intramuscular and oral administration to healthy volunteers</article-title>. <source>European Neurology</source> <volume>49</volume>: <fpage>173</fpage>–<lpage>177</lpage>.</citation>
</ref>
<ref id="bibr47-0004867411432074">
<citation citation-type="journal">
<collab>Cross-National Collaborative Panic Study, Second Phase Investigators</collab> (<year>1992</year>) <article-title>Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine, and placebo</article-title>. <source>British Journal of Psychiatry</source> <volume>160</volume>: <fpage>191</fpage>–<lpage>202</lpage>.</citation>
</ref>
<ref id="bibr48-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Curtis</surname><given-names>GC</given-names></name>
<name><surname>Massana</surname><given-names>J</given-names></name>
<name><surname>Udina</surname><given-names>C</given-names></name><etal/>
</person-group>. (<year>1993</year>) <article-title>Maintenance drug therapy of panic disorder</article-title>. <source>Journal of Psychiatric Research</source> <volume>27</volume>(<supplement>Suppl 1</supplement>): <fpage>127</fpage>–<lpage>142</lpage>.</citation>
</ref>
<ref id="bibr49-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Davidson</surname><given-names>J</given-names></name>
<name><surname>Moroz</surname><given-names>G</given-names></name>
</person-group> (<year>1998</year>) <article-title>Pivotal studies in clonazepam in panic disorder</article-title>. <source>Psychopharmacology Bulletin</source> <volume>34</volume>: <fpage>169</fpage>–<lpage>174</lpage>.</citation>
</ref>
<ref id="bibr50-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dunner</surname><given-names>DL</given-names></name>
<name><surname>Ishiki</surname><given-names>D</given-names></name>
<name><surname>Avery</surname><given-names>DH</given-names></name><etal/>
</person-group>. (<year>1986</year>) <article-title>Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: A controlled study</article-title>. <source>Journal of Clinical Psychiatry</source> <volume>47</volume>: <fpage>458</fpage>–<lpage>460</lpage>.</citation>
</ref>
<ref id="bibr51-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Evans</surname><given-names>R</given-names></name>
</person-group> (<year>1981</year>) <article-title>Alprazolam (Xanax, The Upjohn Company)</article-title>. <source>Drug Intelligence and Clinical Pharmacy</source> <volume>15</volume>: <fpage>633</fpage>–<lpage>638</lpage>.</citation>
</ref>
<ref id="bibr52-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Forrester</surname><given-names>MB</given-names></name>
</person-group> (<year>2006</year>) <article-title>Alprazolam abuse in Texas, 1998–2004</article-title>. <source>Journal of Toxicology and Environmental Health Part A</source> <volume>69</volume>: <fpage>237</fpage>–<lpage>243</lpage>.</citation>
</ref>
<ref id="bibr53-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fyer</surname><given-names>AJ</given-names></name>
<name><surname>Liebowitz</surname><given-names>MR</given-names></name>
<name><surname>Gorman</surname><given-names>JM</given-names></name><etal/>
</person-group>. (<year>1987</year>) <article-title>Discontinuation of alprazolam treatment in panic patients</article-title>. <source>American Journal of Psychiatry</source> <volume>144</volume>: <fpage>303</fpage>–<lpage>308</lpage>.</citation>
</ref>
<ref id="bibr54-0004867411432074">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Galloway</surname><given-names>J</given-names></name>
</person-group> (<year>2007</year>) <source>New Restrictions on the Prescribing of Alprazolam: Information Circular for Pharmacists in Tasmania</source>. <publisher-loc>Hobart</publisher-loc>: <publisher-name>Department of Health and Human Services, Government of Tasmania</publisher-name>.</citation>
</ref>
<ref id="bibr55-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hansen</surname><given-names>M</given-names></name>
<name><surname>Rossow</surname><given-names>I</given-names></name>
</person-group> (<year>2008</year>) <article-title>Adolescent gambling and problem gambling: does the total consumption model apply?</article-title> <source>Journal of Gambling Studies</source> <volume>24</volume>: <fpage>135</fpage>–<lpage>149</lpage>.</citation>
</ref>
<ref id="bibr56-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hayward</surname><given-names>RS</given-names></name>
</person-group> (<year>1997</year>) <article-title>Clinical practice guidelines on trial</article-title>. <source>Canadian Medical Association Journal</source> <volume>156</volume>: <fpage>1725</fpage>–<lpage>1727</lpage>.</citation>
</ref>
<ref id="bibr57-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Herman</surname><given-names>JB</given-names></name>
<name><surname>Rosenbaum</surname><given-names>JF</given-names></name>
<name><surname>Brotman</surname><given-names>A</given-names></name>
</person-group> (<year>1987</year>) <article-title>The alprazolam to clonazepam switch for the treatment of panic disorder</article-title>. <source>Journal of Clinical Psychopharmacology</source> <volume>7</volume>: <fpage>175</fpage>–<lpage>178</lpage>.</citation>
</ref>
<ref id="bibr58-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hernandez</surname><given-names>SH</given-names></name>
<name><surname>Nelson</surname><given-names>LS</given-names></name>
</person-group> (<year>2010</year>) <article-title>Prescription drug abuse: insight into the epidemic</article-title>. <source>Clinical Pharmacology and Therapeutics</source> <volume>88</volume>: <fpage>307</fpage>–<lpage>317</lpage>.</citation>
</ref>
<ref id="bibr59-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hollingworth</surname><given-names>S</given-names></name>
<name><surname>Siskind</surname><given-names>D</given-names></name>
</person-group> (<year>2010</year>) <article-title>Anxiolytic, hypnotic and sedative medication use in Australia</article-title>. <source>Pharmacoepidemiology and Drug Safety</source> <volume>19</volume>: <fpage>280</fpage>–<lpage>288</lpage>.</citation>
</ref>
<ref id="bibr60-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hooper</surname><given-names>S</given-names></name>
<name><surname>Bruno</surname><given-names>R</given-names></name>
<name><surname>Sharpe</surname><given-names>M</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Alprazolam prescribing in Tasmania: a two-fold intervention designed to reduce inappropriate prescribing and concomitant opiate prescription</article-title>. <source>Australasian Psychiatry</source> <volume>17</volume>: <fpage>300</fpage>–<lpage>305</lpage>.</citation>
</ref>
<ref id="bibr61-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Iguchi</surname><given-names>MY</given-names></name>
<name><surname>Griffiths</surname><given-names>RR</given-names></name>
<name><surname>Bickel</surname><given-names>WK</given-names></name><etal/>
</person-group>. (<year>1989</year>) <article-title>Relative abuse liability of benzodiazepines in methadone maintained populations in three cities</article-title>. <source>NIDA Research Monographs</source> <volume>95</volume>: <fpage>364</fpage>–<lpage>365</lpage>.</citation>
</ref>
<ref id="bibr62-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Isbister</surname><given-names>G</given-names></name>
<name><surname>O’Regan</surname><given-names>L</given-names></name>
<name><surname>Sibbritt</surname><given-names>D</given-names></name><etal/>
</person-group>. (<year>2004</year>) <article-title>Alprazolam is relatively more toxic than other benzodiazepines in overdose</article-title>. <source>British Journal of Clinical Pharmacology</source> <volume>58</volume>: <fpage>88</fpage>–<lpage>95</lpage>.</citation>
</ref>
<ref id="bibr63-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jonas</surname><given-names>J</given-names></name>
<name><surname>Cohon</surname><given-names>M</given-names></name>
</person-group> (<year>1993</year>) <article-title>A comparison of the safety and efficacy of alprazolam versus other agents in the treatment of anxiety, panic, and depression: a review of the literature</article-title>. <source>Journal of Clinical Psychiatry</source> <volume>54</volume>: <fpage>25</fpage>–<lpage>45</lpage>.</citation>
</ref>
<ref id="bibr64-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Juergens</surname><given-names>S</given-names></name>
</person-group> (<year>1991</year>) <article-title>Alprazolam and diazepam: Addiction potential</article-title>. <source>Journal of Substance Abuse Treatment</source> <volume>8</volume>: <fpage>43</fpage>–<lpage>51</lpage>.</citation>
</ref>
<ref id="bibr65-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kales</surname><given-names>A</given-names></name>
<name><surname>Bixler</surname><given-names>EO</given-names></name>
<name><surname>Vela-Bueno</surname><given-names>A</given-names></name><etal/>
</person-group>. (<year>1987</year>) <article-title>Alprazolam: effects on sleep and withdrawal phenomena</article-title>. <source>Journal of Clinical Pharmacology</source> <volume>27</volume>: <fpage>508</fpage>–<lpage>515</lpage>.</citation>
</ref>
<ref id="bibr66-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kessler</surname><given-names>RC</given-names></name>
<name><surname>Chiu</surname><given-names>WT</given-names></name>
<name><surname>Jin</surname><given-names>R</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication</article-title>. <source>Archives of General Psychiatry</source> <volume>63</volume>: <fpage>415</fpage>–<lpage>424</lpage>.</citation>
</ref>
<ref id="bibr67-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Klerman</surname><given-names>G</given-names></name>
</person-group> (<year>1988</year>) <article-title>Overview of the cross-national collaborative panic study</article-title>. <source>Archives of General Psychiatry</source> <volume>45</volume>: <fpage>407</fpage>–<lpage>412</lpage>.</citation>
</ref>
<ref id="bibr68-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lesser</surname><given-names>IM</given-names></name>
</person-group> (<year>1991</year>) <article-title>The treatment of panic disorders: Pharmacologic aspects</article-title>. <source>Psychiatric Annals</source> <volume>21</volume>: <fpage>341</fpage>–<lpage>346</lpage>.</citation>
</ref>
<ref id="bibr69-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Leufkens</surname><given-names>T</given-names></name>
<name><surname>Vermeeren</surname><given-names>A</given-names></name>
<name><surname>Smink</surname><given-names>B</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Cognitive, psychomotor and actual driving performance in healthy volunteers after immediate and extended release formulations of alprazolam 1 mg</article-title>. <source>Psychopharmacology</source> <volume>191</volume>: <fpage>951</fpage>–<lpage>959</lpage>.</citation>
</ref>
<ref id="bibr70-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lomas</surname><given-names>J</given-names></name>
<name><surname>Anderson</surname><given-names>GM</given-names></name>
<name><surname>Domnick-Pierre</surname><given-names>K</given-names></name><etal/>
</person-group>. (<year>1989</year>) <article-title>Do practice guidelines guide practice? The effect of a consensus statement on the practice of physicians</article-title>. <source>New England Journal of Medicine</source> <volume>321</volume>: <fpage>1306</fpage>–<lpage>1311</lpage>.</citation>
</ref>
<ref id="bibr71-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Malhi</surname><given-names>GS</given-names></name>
<name><surname>Adams</surname><given-names>D</given-names></name>
<name><surname>Cahill</surname><given-names>CM</given-names></name><etal/>
</person-group>. (<year>2009a</year>) <article-title>The management of individuals with bipolar disorder: a review of the evidence and its integration into clinical practice</article-title>. <source>Drugs</source> <volume>69</volume>: <fpage>2063</fpage>–<lpage>2101</lpage>.</citation>
</ref>
<ref id="bibr72-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Malhi</surname><given-names>GS</given-names></name>
<name><surname>Adams</surname><given-names>D</given-names></name>
<name><surname>Porter</surname><given-names>R</given-names></name><etal/>
</person-group>. (<year>2009b</year>) <article-title>Clinical practice recommendations for depression</article-title>. <source>Acta Psychiatrica Scandanavica Supplement</source> <volume>439</volume>: <fpage>8</fpage>–<lpage>26</lpage>.</citation>
</ref>
<ref id="bibr73-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Marks</surname><given-names>I</given-names></name>
<name><surname>De Albuquerque</surname><given-names>A</given-names></name>
<name><surname>Cottraux</surname><given-names>J</given-names></name><etal/>
</person-group>. (<year>1989</year>) <article-title>The ‘efficacy’ of alprazolam in panic disorder and agoraphobia: A critique of recent reports</article-title>. <source>Archives of General Psychiatry</source> <volume>46</volume>: <fpage>668</fpage>–<lpage>670</lpage>.</citation>
</ref>
<ref id="bibr74-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mavissakalian</surname><given-names>MR</given-names></name>
<name><surname>Perel</surname><given-names>JM</given-names></name>
</person-group> (<year>2002</year>) <article-title>Duration of imipramine therapy and relapse in panic disorder with agoraphobia</article-title>. <source>Journal of Clinical Psychopharmacology</source> <volume>22</volume>: <fpage>294</fpage>–<lpage>299</lpage>.</citation>
</ref>
<ref id="bibr75-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meco</surname><given-names>G</given-names></name>
<name><surname>Capriani</surname><given-names>C</given-names></name>
<name><surname>Bonifati</surname><given-names>U</given-names></name><etal/>
</person-group>. (<year>1989</year>) <article-title>Etizolam: A new therapeutics possibility in the treatment of panic disorder</article-title>. <source>Advances in Therapy</source> <volume>6</volume>: <fpage>196</fpage>–<lpage>206</lpage>.</citation>
</ref>
<ref id="bibr76-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mitte</surname><given-names>K</given-names></name>
</person-group> (<year>2005</year>) <article-title>A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia</article-title>. <source>Journal of Affective Disorders</source> <volume>88</volume>: <fpage>27</fpage>–<lpage>45</lpage>.</citation>
</ref>
<ref id="bibr77-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Moroz</surname><given-names>G</given-names></name>
<name><surname>Rosenbaum</surname><given-names>JF</given-names></name>
</person-group> (<year>1999</year>) <article-title>Efficacy, safety, and gradual discontinuation of clonazepam in panic disorder: a placebo-controlled, multicenter study using optimized dosages</article-title>. <source>Journal of Clinical Psychiatry</source> <volume>60</volume>: <fpage>604</fpage>–<lpage>612</lpage>.</citation>
</ref>
<ref id="bibr78-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Moylan</surname><given-names>S</given-names></name>
<name><surname>Staples</surname><given-names>J</given-names></name>
<name><surname>Ward</surname><given-names>S</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>The efficacy and safety of alprazolam versus other benzodiazepines in the treatment of panic disorder</article-title>. <source>Journal of Clinical Psychopharmacology</source> <volume>31</volume>: <fpage>647</fpage>–<lpage>652</lpage>.</citation>
</ref>
<ref id="bibr79-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mumford</surname><given-names>G</given-names></name>
<name><surname>Evans</surname><given-names>S</given-names></name>
<name><surname>Fleishaker</surname><given-names>J</given-names></name><etal/>
</person-group>. (<year>1995</year>) <article-title>Alprazolam absorption kinetics affects abuse liability</article-title>. <source>Clinical Pharmacology and Therapeutics</source> <volume>57</volume>: <fpage>356</fpage>–<lpage>365</lpage>.</citation>
</ref>
<ref id="bibr80-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nagy</surname><given-names>LM</given-names></name>
<name><surname>Krystal</surname><given-names>JH</given-names></name>
<name><surname>Woods</surname><given-names>SW</given-names></name><etal/>
</person-group>. (<year>1989</year>) <article-title>Outcome after short-term alprazolam and behavorial group treatment in panic disorder: 2.5-year naturalistic follow-up study</article-title>. <source>Archives of General Psychiatry</source> <volume>46</volume>: <fpage>993</fpage>–<lpage>999</lpage>.</citation>
</ref>
<ref id="bibr81-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nardi</surname><given-names>A</given-names></name>
<name><surname>Freire</surname><given-names>R</given-names></name>
<name><surname>Valenca</surname><given-names>A</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Tapering clonazepam in patients with panic disorder after at least 3 years of treatment</article-title>. <source>Journal of Clinical Psychopharmacology</source> <volume>30</volume>: <fpage>290</fpage>–<lpage>293</lpage>.</citation>
</ref>
<ref id="bibr82-0004867411432074">
<citation citation-type="book">
<collab>National Institute for Health and Clinical Excellence (NICE)</collab> (<year>2011</year>) <article-title>Anxiety</article-title>. <source>NICE Guideline CG113 (update 2011)</source>. <publisher-loc>London</publisher-loc>: <publisher-name>NICE</publisher-name>.</citation>
</ref>
<ref id="bibr83-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ng</surname><given-names>F</given-names></name>
<name><surname>Hallam</surname><given-names>K</given-names></name>
<name><surname>Lucas</surname><given-names>N</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>The role of lamotrigine in the management of bipolar disorder</article-title>. <source>Neuropsychiatric Disease and Treatment</source> <volume>3</volume>: <fpage>463</fpage>–<lpage>474</lpage>.</citation>
</ref>
<ref id="bibr84-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Noyes</surname><given-names>R</given-names><suffix>Jr</suffix></name>
<name><surname>Burrows</surname><given-names>GD</given-names></name>
<name><surname>Reich</surname><given-names>JH</given-names></name><etal/>
</person-group>. (<year>1996</year>) <article-title>Diazepam versus alprazolam for the treatment of panic disorder</article-title>. <source>Journal of Clinical Psychiatry</source> <volume>57</volume>: <fpage>349</fpage>–<lpage>355</lpage>.</citation>
</ref>
<ref id="bibr85-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Noyes</surname><given-names>R</given-names><suffix>Jr</suffix></name>
<name><surname>DuPont</surname><given-names>RL</given-names><suffix>Jr</suffix></name>
<name><surname>Pecknold</surname><given-names>JC</given-names></name><etal/>
</person-group>. (<year>1988</year>) <article-title>Alprazolam in panic disorder and agoraphobia: Results from a multicenter trial. II. Patient acceptance, side effects, and safety</article-title>. <source>Archives of General Psychiatry</source> <volume>45</volume>: <fpage>423</fpage>–<lpage>428</lpage>.</citation>
</ref>
<ref id="bibr86-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Noyes</surname><given-names>R</given-names><suffix>Jr</suffix></name>
<name><surname>Garvey</surname><given-names>MJ</given-names></name>
<name><surname>Cook</surname><given-names>B</given-names></name><etal/>
</person-group>. (<year>1991</year>) <article-title>Controlled discontinuation of benzodiazepine treatment for patients with panic disorder</article-title>. <source>American Journal of Psychiatry</source> <volume>148</volume>: <fpage>517</fpage>–<lpage>523</lpage>.</citation>
</ref>
<ref id="bibr87-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Brien</surname><given-names>C</given-names></name>
</person-group> (<year>2005</year>) <article-title>Benzodiazepine use, abuse, and dependence</article-title>. <source>Journal of Clinical Psychiatry</source> <volume>66</volume>: <fpage>28</fpage>–<lpage>33</lpage>.</citation>
</ref>
<ref id="bibr88-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Sullivan</surname><given-names>G</given-names></name>
<name><surname>Noshirvani</surname><given-names>H</given-names></name>
<name><surname>Basoglu</surname><given-names>M</given-names></name><etal/>
</person-group>. (<year>1994</year>) <article-title>Safety and side-effects of alprazolam. Controlled study in agoraphobia with panic disorder</article-title>. <source>British Journal of Psychiatry</source> <volume>165</volume>: <fpage>79</fpage>–<lpage>86</lpage>.</citation>
</ref>
<ref id="bibr89-0004867411432074">
<citation citation-type="confproc">
<person-group person-group-type="author">
<name><surname>Ogden</surname><given-names>E</given-names></name>
<name><surname>Morris</surname><given-names>C</given-names></name>
<name><surname>Frederiksen</surname><given-names>T</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>The relationship between accident culpability and the presence of drugs in blood samples taken from people injured in motor vehicle collisions</article-title>. In: <collab>AustRoads</collab> (ed.) <conf-name>Australasian Road Safety Research, Policing and Education Conference</conf-name>.</citation>
</ref>
<ref id="bibr90-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Otto</surname><given-names>M</given-names></name>
<name><surname>Tuby</surname><given-names>K</given-names></name>
<name><surname>Gould</surname><given-names>R</given-names></name><etal/>
</person-group>. (<year>2001</year>) <article-title>An effect-size analysis of the relative efficacy and tolerability of selective serotonin reuptake inhibitors for panic disorder</article-title>. <source>American Journal of Psychiatry</source> <volume>158</volume>: <fpage>1989</fpage>–<lpage>1992</lpage>.</citation>
</ref>
<ref id="bibr91-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pecknold</surname><given-names>JC</given-names></name>
</person-group> (<year>1993</year>) <article-title>Discontinuation reactions to alprazolam in panic disorder</article-title>. <source>Journal of Psychiatric Research</source> <volume>27</volume>: <fpage>155</fpage>–<lpage>170</lpage>.</citation>
</ref>
<ref id="bibr92-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pecknold</surname><given-names>JC</given-names></name>
<name><surname>Swinson</surname><given-names>RP</given-names></name>
<name><surname>Kuch</surname><given-names>K</given-names></name><etal/>
</person-group>. (<year>1988</year>) <article-title>Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. III. Discontinuation effects</article-title>. <source>Archives of General Psychiatry</source> <volume>5</volume>: <fpage>429</fpage>–<lpage>436</lpage>.</citation>
</ref>
<ref id="bibr93-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Perna</surname><given-names>G</given-names></name>
<name><surname>Bertani</surname><given-names>A</given-names></name>
<name><surname>Caldirola</surname><given-names>D</given-names></name><etal/>
</person-group>. (<year>2001</year>) <article-title>A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study</article-title>. <source>Pharmacopsychiatry</source> <volume>34</volume>: <fpage>85</fpage>–<lpage>90</lpage>.</citation>
</ref>
<ref id="bibr94-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Peters</surname><given-names>RJ</given-names></name>
<name><surname>Meshack</surname><given-names>A</given-names></name>
<name><surname>Kelder</surname><given-names>S</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Alprazolam (Xanax) use among southern youth: beliefs and social norms concerning dangerous rides on ‘handlebars’</article-title>. <source>Journal of Drug Education</source> <volume>37</volume>: <fpage>417</fpage>–<lpage>428</lpage>.</citation>
</ref>
<ref id="bibr95-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pollack</surname><given-names>MH</given-names></name>
<name><surname>Lepola</surname><given-names>U</given-names></name>
<name><surname>Koponen</surname><given-names>H</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder</article-title>. <source>Depression and Anxiety</source> <volume>24</volume>: <fpage>1</fpage>–<lpage>14</lpage>.</citation>
</ref>
<ref id="bibr96-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pollack</surname><given-names>MH</given-names></name>
<name><surname>Otto</surname><given-names>MW</given-names></name>
<name><surname>Tesar</surname><given-names>GE</given-names></name><etal/>
</person-group>. (<year>1993</year>) <article-title>Long-term outcome after acute treatment with alprazolam or clonazepam for panic disorder</article-title>. <source>Journal of Clinical Psychopharmacology</source> <volume>13</volume>: <fpage>257</fpage>–<lpage>263</lpage>.</citation>
</ref>
<ref id="bibr97-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pyke</surname><given-names>RE</given-names></name>
<name><surname>Greenberg</surname><given-names>HS</given-names></name>
</person-group> (<year>1989</year>) <article-title>Double-blind comparison of alprazolam and adinazolam for panic and phobic disorders</article-title>. <source>Journal of Clinical Psychopharmacology</source> <volume>1</volume>: <fpage>15</fpage>–<lpage>21</lpage>.</citation>
</ref>
<ref id="bibr98-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rapoport</surname><given-names>M</given-names></name>
<name><surname>Lanctot</surname><given-names>K</given-names></name>
<name><surname>Streiner</surname><given-names>D</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Benzodiazepine use and driving: a meta-analysis</article-title>. <source>Journal of Clinical Psychiatry</source> <volume>70</volume>: <fpage>1727</fpage>–<lpage>1729</lpage>.</citation>
</ref>
<ref id="bibr99-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rickels</surname><given-names>K</given-names></name>
<name><surname>Schweizer</surname><given-names>E</given-names></name>
</person-group> (<year>1998</year>) <article-title>Panic disorder: long-term pharmacotherapy and discontinuation</article-title>. <source>Journal of Clinical Psychopharmacology</source> <volume>18</volume>: <fpage>12S</fpage>–<lpage>18S</lpage>.</citation>
</ref>
<ref id="bibr100-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rizley</surname><given-names>R</given-names></name>
<name><surname>Kahn</surname><given-names>RJ</given-names></name>
<name><surname>McNair</surname><given-names>DM</given-names></name><etal/>
</person-group>. (<year>1986</year>) <article-title>A comparison of alprazolam and imipramine in the treatment of agoraphobia and panic disorder</article-title>. <source>Psychopharmacology Bulletin</source> <volume>1</volume>: <fpage>167</fpage>–<lpage>172</lpage>.</citation>
</ref>
<ref id="bibr101-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Romach</surname><given-names>M</given-names></name>
<name><surname>Busto</surname><given-names>U</given-names></name>
<name><surname>Sobell</surname><given-names>L</given-names></name><etal/>
</person-group>. (<year>1991</year>) <article-title>Long-term alprazolam use: abuse, dependence or treatment?</article-title> <source>Psychopharmacology Bulletin</source> <volume>27</volume>: <fpage>391</fpage>–<lpage>395</lpage>.</citation>
</ref>
<ref id="bibr102-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Romach</surname><given-names>M</given-names></name>
<name><surname>Somer</surname><given-names>G</given-names></name>
<name><surname>Sobell</surname><given-names>L</given-names></name><etal/>
</person-group>. (<year>1992</year>) <article-title>Characteristics of long-term alprazolam users in the community</article-title>. <source>Journal of Clinical Psychopharmacology</source> <volume>12</volume>: <fpage>316</fpage>–<lpage>321</lpage>.</citation>
</ref>
<ref id="bibr103-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rosenbaum</surname><given-names>JF</given-names></name>
</person-group> (<year>1993</year>) <article-title>Long-term outcome after acute treatment with alprazolam or clonazepam for panic disorder</article-title>. <source>Journal of Clinical Psychopharmacology</source> <volume>13</volume>: <fpage>257</fpage>–<lpage>263</lpage>.</citation>
</ref>
<ref id="bibr104-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rosenbaum</surname><given-names>JF</given-names></name>
</person-group> (<year>2004</year>) <article-title>The development of clonazepam as a psychotropic: The Massachusetts General Hospital experience</article-title>. <source>Journal of Clinical Psychiatry</source> <volume>65</volume>: <fpage>3</fpage>–<lpage>6</lpage>.</citation>
</ref>
<ref id="bibr105-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rosenbaum</surname><given-names>JF</given-names></name>
<name><surname>Moroz</surname><given-names>G</given-names></name>
<name><surname>Bowden</surname><given-names>CL</given-names></name>
</person-group> (<year>1997</year>) <article-title>Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose-response study of efficacy, safety, and discontinuance. Clonazepam Panic Disorder Dose-Response Study Group</article-title>. <source>Journal of Clinical Psychopharmacology</source> <volume>17</volume>: <fpage>390</fpage>–<lpage>400</lpage>.</citation>
</ref>
<ref id="bibr106-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Roy-Byrne</surname><given-names>PP</given-names></name>
<name><surname>Hommer</surname><given-names>D</given-names></name>
</person-group> (<year>1988</year>) <article-title>Benzodiazepine withdrawal: overview and implications for the treatment of anxiety</article-title>. <source>American Journal of Medicine</source> <volume>84</volume>: <fpage>1041</fpage>–<lpage>1052</lpage>.</citation>
</ref>
<ref id="bibr107-0004867411432074">
<citation citation-type="journal">
<collab>Royal Australian and New Zealand College of Psychiatrists (RANZCP)</collab> (<year>2003</year>): <article-title>Guidelines Team for Panic Disorder and Agoraphobia. Australian and New Zealand clinical practice guidelines for the treatment of panic disorder and agoraphobia</article-title>. <source>Australian and New Zealand Journal of Psychiatry</source> <volume>37</volume>: <fpage>641</fpage>–<lpage>656</lpage>.</citation>
</ref>
<ref id="bibr108-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rush</surname><given-names>CR</given-names></name>
<name><surname>Higgins</surname><given-names>ST</given-names></name>
<name><surname>Bickel</surname><given-names>WK</given-names></name><etal/>
</person-group>. (<year>1993</year>) <article-title>Abuse liability of alprazolam relative to other commonly used benzodiazepines: a review</article-title>. <source>Neuroscience and Biobehavioral Reviews</source> <volume>17</volume>: <fpage>277</fpage>–<lpage>285</lpage>.</citation>
</ref>
<ref id="bibr109-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Saida</surname><given-names>F</given-names></name>
<name><surname>Svjetlana</surname><given-names>LZ</given-names></name>
</person-group> (<year>2005</year>) <article-title>Sertraline and alprazolam in the treatment of panic [sic] desorder</article-title>. <source>Bosnian Journal of Basic Medical Sciences</source> <volume>5</volume>: <fpage>78</fpage>–<lpage>81</lpage>.</citation>
</ref>
<ref id="bibr110-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Salzman</surname><given-names>C</given-names></name>
</person-group> (<year>1991</year>) <article-title>The APA Task Force report on benzodiazepine dependence, toxicity, and abuse</article-title>. <source>American Journal of Psychiatry</source> <volume>148</volume>: <fpage>151</fpage>.</citation>
</ref>
<ref id="bibr111-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schweizer</surname><given-names>E</given-names></name>
<name><surname>Fox</surname><given-names>I</given-names></name>
<name><surname>Case</surname><given-names>G</given-names></name><etal/>
</person-group>. (<year>1988</year>) <article-title>Lorazepam vs. alprazolam in the treatment of panic disorder</article-title>. <source>Psychopharmacology Bulletin</source> <volume>24</volume>: <fpage>224</fpage>–<lpage>227</lpage>.</citation>
</ref>
<ref id="bibr112-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schweizer</surname><given-names>E</given-names></name>
<name><surname>Pohl</surname><given-names>R</given-names></name>
<name><surname>Balon</surname><given-names>R</given-names></name><etal/>
</person-group>. (<year>1990</year>) <article-title>Lorazepam vs. alprazolam in the treatment of panic disorder</article-title>. <source>Pharmacopsychiatry</source> <volume>23</volume>: <fpage>90</fpage>–<lpage>93</lpage>.</citation>
</ref>
<ref id="bibr113-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schweizer</surname><given-names>E</given-names></name>
<name><surname>Rickels</surname><given-names>K</given-names></name>
<name><surname>Weiss</surname><given-names>S</given-names></name><etal/>
</person-group>. (<year>1993</year>) <article-title>Maintenance drug treatment of panic disorder: I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine</article-title>. <source>Archives of General Psychiatry</source> <volume>50</volume>: <fpage>51</fpage>–<lpage>60</lpage>.</citation>
</ref>
<ref id="bibr114-0004867411432074">
<citation citation-type="gov">
<collab>SDI/Verispan L</collab> (<year>2008a</year>) <article-title>Vector One: National (VONA) Health Analytics Data</article-title>. <year>2008</year>. <comment>Accessed via Substance Abuse and Mental Health Services Administration. Available at: <ext-link ext-link-type="uri" xlink:href="http://nac.samhsa.gov/DTAB/Presentations/Aug08/SeanBelouinDTAB0808.ppt">http://nac.samhsa.gov/DTAB/Presentations/Aug08/SeanBelouinDTAB0808.ppt</ext-link></comment> (<access-date>accessed 22 August 2011</access-date>).</citation>
</ref>
<ref id="bibr115-0004867411432074">
<citation citation-type="web">
<collab>SDI/Verispan</collab> (<year>2008b</year>) <article-title>2008 Top 200 generic drugs by total prescriptions</article-title>. <comment>Available at: <ext-link ext-link-type="uri" xlink:href="http://drugtopics.modernmedicine.com/top200gen">http://drugtopics.modernmedicine.com/top200gen</ext-link></comment> (<access-date>accessed 3 August 2010</access-date>).</citation>
</ref>
<ref id="bibr116-0004867411432074">
<citation citation-type="web">
<collab>SDI/Verispan</collab> (<year>2010</year>) <article-title>2009 Top 200 generic drugs by total prescriptions</article-title>. <comment>Available at: <ext-link ext-link-type="uri" xlink:href="http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard/drugtopics/252010/674982/article.pdf">http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard/drugtopics/252010/674982/article.pdf</ext-link></comment> (<access-date>accessed 3 August 2010</access-date>).</citation>
</ref>
<ref id="bibr117-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sellers</surname><given-names>E</given-names></name>
<name><surname>Ciraulo</surname><given-names>D</given-names></name>
<name><surname>DuPont</surname><given-names>R</given-names></name><etal/>
</person-group>. (<year>1993</year>) <article-title>Alprazolam and benzodiazepine dependence</article-title>. <source>Journal of Clinical Psychiatry</source> <volume>54</volume>: <fpage>64</fpage>–<lpage>75</lpage>.</citation>
</ref>
<ref id="bibr118-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shear</surname><given-names>M</given-names></name>
<name><surname>Brown</surname><given-names>T</given-names></name>
<name><surname>Barlow</surname><given-names>D</given-names></name><etal/>
</person-group>. (<year>1997</year>) <article-title>Multicenter collaborative panic disorder severity scale</article-title>. <source>American Journal of Psychiatry</source> <volume>154</volume>: <fpage>1571</fpage>–<lpage>1575</lpage>.</citation>
</ref>
<ref id="bibr119-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sheehan</surname><given-names>DV</given-names></name>
</person-group> (<year>1987</year>) <article-title>Benzodiazepines in panic disorder and agoraphobia</article-title>. <source>Journal of Affective Disorders</source> <volume>13</volume>: <fpage>169</fpage>–<lpage>181</lpage>.</citation>
</ref>
<ref id="bibr120-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Simon</surname><given-names>NM</given-names></name>
<name><surname>Otto</surname><given-names>MW</given-names></name>
<name><surname>Worthington</surname><given-names>JJ</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Next-step strategies for panic disorder refractory to initial pharmacotherapy: a 3-phase randomized clinical trial</article-title>. <source>Journal of Clinical Psychiatry</source> <volume>70</volume>: <fpage>1563</fpage>–<lpage>1570</lpage>.</citation>
</ref>
<ref id="bibr121-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Skog</surname><given-names>OJ</given-names></name>
<name><surname>Rossow</surname><given-names>I</given-names></name>
</person-group> (<year>2006</year>) <article-title>Flux and stability: individual fluctuations, regression towards the mean and collective changes in alcohol consumption</article-title>. <source>Addiction</source> <volume>101</volume>: <fpage>959</fpage>–<lpage>970</lpage>.</citation>
</ref>
<ref id="bibr122-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Smink</surname><given-names>B</given-names></name>
<name><surname>Egberts</surname><given-names>A</given-names></name>
<name><surname>Lusthof</surname><given-names>K</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>The relationship between benzodiazepine use and traffic accidents: A systematic literature review</article-title>. <source>CNS Drugs</source> <volume>24</volume>: <fpage>639</fpage>–<lpage>653</lpage>.</citation>
</ref>
<ref id="bibr123-0004867411432074">
<citation citation-type="gov">
<collab>Substance Abuse and Mental Health Services Administration, Office of Applied Statistics</collab> (<year>2010</year>) <article-title>Drug Abuse Warning Network, 2007: <italic>National Estimates of Drug-Related Emergency Department Visits. U.S. Department of Health and Human Services</italic></article-title>. <month>May</month> <year>2010</year>. <publisher-loc>Rockville</publisher-loc>; (<comment>cited 2 Feb 2011</comment>) <comment>&gt;Available from: <ext-link ext-link-type="uri" xlink:href="http://dawninfo.samhsa.gov/files/ed2007/dawn2k7ed.pdf">http://dawninfo.samhsa.gov/files/ed2007/dawn2k7ed.pdf</ext-link></comment></citation>
</ref>
<ref id="bibr124-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tan</surname><given-names>KR</given-names></name>
<name><surname>Brown</surname><given-names>M</given-names></name>
<name><surname>Labouebe</surname><given-names>G</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Neural bases for addictive properties of benzodiazepines</article-title>. <source>Nature</source> <volume>463</volume>: <fpage>769</fpage>–<lpage>774</lpage>.</citation>
</ref>
<ref id="bibr125-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tesar</surname><given-names>GE</given-names></name>
<name><surname>Rosenbaum</surname><given-names>JF</given-names></name>
<name><surname>Pollack</surname><given-names>MH</given-names></name><etal/>
</person-group>. (<year>1987</year>) <article-title>Clonazepam versus alprazolam in the treatment of panic disorder: interim analysis of data from a prospective, double-blind, placebo-controlled trial</article-title>. <source>Journal of Clinical Psychiatry</source> <volume>48</volume>(<supplement>Suppl</supplement>): <fpage>16</fpage>–<lpage>21</lpage>.</citation>
</ref>
<ref id="bibr126-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tesar</surname><given-names>GE</given-names></name>
<name><surname>Rosenbaum</surname><given-names>JF</given-names></name>
<name><surname>Pollack</surname><given-names>MH</given-names></name><etal/>
</person-group>. (<year>1991</year>) <article-title>Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder</article-title>. <source>Journal of Clinical Psychiatry</source> <volume>2</volume>: <fpage>69</fpage>–<lpage>76</lpage>.</citation>
</ref>
<ref id="bibr127-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Toni</surname><given-names>C</given-names></name>
<name><surname>Perugi</surname><given-names>G</given-names></name>
<name><surname>Frare</surname><given-names>F</given-names></name><etal/>
</person-group>. (<year>2000</year>) <article-title>A prospective naturalistic study of 326 panic-agoraphobic patients treated with antidepressants</article-title>. <source>Pharmacopsychiatry</source> <volume>33</volume>: <fpage>121</fpage>–<lpage>131</lpage>.</citation>
</ref>
<ref id="bibr128-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vermeeren</surname><given-names>A</given-names></name>
<name><surname>Jackson</surname><given-names>J</given-names></name>
<name><surname>Muntjewerff</surname><given-names>N</given-names></name><etal/>
</person-group>. (<year>1995</year>) <article-title>Comparison of acute alprazolam (0.25, 0.50 and 1.0 mg) effects versus those of lorazepam 2 mg and placebo on memory in health volunteers using laboratory and telephone tests</article-title>. <source>Psychopharmacology</source> <volume>118</volume>: <fpage>1</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr129-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Verster</surname><given-names>J</given-names></name>
<name><surname>Volkerts</surname><given-names>E</given-names></name>
</person-group> (<year>2004</year>) <article-title>Clinical pharmacology, clinical efficacy, and behavioral toxicity of alprazolam: A review of the literature</article-title>. <source>CNS Drugs</source> <volume>10</volume>: <fpage>45</fpage>–<lpage>76</lpage>.</citation>
</ref>
<ref id="bibr130-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Verster</surname><given-names>J</given-names></name>
<name><surname>Volkerts</surname><given-names>E</given-names></name>
<name><surname>Verbaten</surname><given-names>M</given-names></name>
</person-group> (<year>2002</year>) <article-title>Effects of alprazolam on driving ability, memory functioning and psychomotor performance: a randomized, placebo-controlled study</article-title>. <source>Neuropsychopharmacology</source> <volume>27</volume>: <fpage>260</fpage>–<lpage>269</lpage>.</citation>
</ref>
<ref id="bibr131-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vittone</surname><given-names>B</given-names></name>
<name><surname>Uhde</surname><given-names>T</given-names></name>
</person-group> (<year>1985</year>) <article-title>Differential diagnosis and treatment of panic disorder: a medical model perspective</article-title>. <source>Australian and New Zealand Journal of Psychiatry</source> <volume>19</volume>: <fpage>330</fpage>–<lpage>341</lpage>.</citation>
</ref>
<ref id="bibr132-0004867411432074">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Webber</surname><given-names>T</given-names></name>
</person-group> (<year>2009</year>) <source>Professional Service Review: Annual Report 2009</source>. <publisher-loc>Canberra, ACT</publisher-loc>: <publisher-name>Commonwealth Government of Australia</publisher-name>.</citation>
</ref>
<ref id="bibr133-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Westernberg</surname><given-names>H</given-names></name>
</person-group> (<year>1996</year>) <article-title>Developments in the drug treatment of panic disorder: what is the place of the selective serotonin reuptake inhibitors?</article-title> <source>Journal of Affective Disorders</source> <volume>40</volume>: <fpage>85</fpage>–<lpage>93</lpage>.</citation>
</ref>
<ref id="bibr134-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Westra</surname><given-names>HA</given-names></name>
<name><surname>Stewart</surname><given-names>SH</given-names></name>
<name><surname>Conrad</surname><given-names>BE</given-names></name>
</person-group> (<year>2002</year>) <article-title>Naturalistic manner of benzodiazepine use and cognitive behavioral therapy outcome in panic disorder with agoraphobia</article-title>. <source>Journal of Anxiety Disorders</source> <volume>16</volume>: <fpage>233</fpage>–<lpage>246</lpage>.</citation>
</ref>
<ref id="bibr135-0004867411432074">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wolf</surname><given-names>B</given-names></name>
<name><surname>Griffiths</surname><given-names>R</given-names></name>
</person-group> (<year>1991</year>) <article-title>Physical dependence on benzodiazepines: differences within the class</article-title>. <source>Drug and Alcohol Dependence</source> <volume>29</volume>: <fpage>153</fpage>–<lpage>156</lpage>.</citation>
</ref>
<ref id="bibr136-0004867411432074">
<citation citation-type="web">
<collab>World Health Organization</collab> (<year>2011a</year>) <article-title>WHO Collaborating Centre for Drug Statistics Methodology</article-title>. <comment>Available at: <ext-link ext-link-type="uri" xlink:href="http://www.whocc.no/">www.whocc.no/</ext-link></comment> (<access-date>accessed 14 September 2011</access-date>).</citation>
</ref>
<ref id="bibr137-0004867411432074">
<citation citation-type="web">
<collab>World Health Organization (WHO)</collab> (<year>2011b</year>) <article-title>Lexicon of alcohol and drug terms published by the World Health Organization</article-title>. <comment>Available at: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/substance_abuse/terminology/who_lexicon/en/">www.who.int/substance_abuse/terminology/who_lexicon/en/</ext-link></comment> (<access-date>accessed 28 August 2011</access-date>).</citation>
</ref>
</ref-list>
</back>
</article>